{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:04:32Z","timestamp":1793639072929,"version":"4.5.1"},"reference-count":262,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Opening Foundation of the State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine","award":["SKLID2025KF01"],"award-info":[{"award-number":["SKLID2025KF01"]}],"id":[{"id":"https:\/\/ror.org\/05m1p5x56","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Key Nature Science Foundation of Zhejiang Province","award":["LZ24H160005"],"award-info":[{"award-number":["LZ24H160005"]}]},{"name":"the Fundamental Research Funds for the Central Universities","award":["226-2025-00249"],"award-info":[{"award-number":["226-2025-00249"]}]},{"name":"the Central Guidance Fund for Local Science and Technology Development","award":["2024ZY01054"],"award-info":[{"award-number":["2024ZY01054"]}]},{"name":"Zhejiang Provincial Natural Science Foundation of China","award":["LQ24H030003"],"award-info":[{"award-number":["LQ24H030003"]}],"id":[{"id":"https:\/\/ror.org\/04aqat463","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-026-02692-9","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T06:57:56Z","timestamp":1779346676000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["JAK-STAT signaling pathway in cancer: from molecular mechanisms to clinical intervention"],"prefix":"10.1186","volume":"25","author":[{"given":"Xiaoqian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penghui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuqiang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuokai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfei","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihui","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"2692_CR1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1146\/annurev.immunol.16.1.293","volume":"16","author":"WJ Leonard","year":"1998","unstructured":"Leonard WJ, O\u2019Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol. 1998;16:293\u2013322.","journal-title":"Annu Rev Immunol"},{"key":"2692_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0168-9525(97)01006-8","volume":"13","author":"XS Hou","year":"1997","unstructured":"Hou XS, Perrimon N. The JAK-STAT pathway in Drosophila. Trends Genet. 1997;13:105\u201310.","journal-title":"Trends Genet"},{"key":"2692_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nsmb.3378","volume":"24","author":"KI Arimoto","year":"2017","unstructured":"Arimoto KI, L\u00f6chte S, Stoner SA, Burkart C, Zhang Y, Miyauchi S, et al. STAT2 is an essential adaptor in USP18-mediated suppression of type I interferon signaling. Nat Struct Mol Biol. 2017;24:279\u201389.","journal-title":"Nat Struct Mol Biol"},{"key":"2692_CR4","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1007\/s10875-023-01483-x","volume":"43","author":"N Ott","year":"2023","unstructured":"Ott N, Faletti L, Heeg M, Andreani V. JAKs and STATs from a Clinical Perspective: Loss-of-Function Mutations, Gain-of-Function Mutations, and Their Multidimensional Consequences. J Clin Immunol. 2023;43:1326\u201359.","journal-title":"J Clin Immunol"},{"key":"2692_CR5","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1056\/NEJMoa1114885","volume":"366","author":"HL Koskela","year":"2012","unstructured":"Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanm\u00e4ki H, Andersson EI, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012;366:1905\u201313.","journal-title":"N Engl J Med"},{"key":"2692_CR6","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1093\/carcin\/bgab075","volume":"42","author":"HE Sabaawy","year":"2021","unstructured":"Sabaawy HE, Ryan BM, Khiabanian H, Pine SR. JAK\/STAT of all trades: linking inflammation with cancer development, tumor progression and therapy resistance. Carcinogenesis. 2021;42:1411\u20139.","journal-title":"Carcinogenesis"},{"key":"2692_CR7","doi-asserted-by":"publisher","first-page":"1068260","DOI":"10.3389\/fimmu.2022.1068260","volume":"13","author":"IH Huang","year":"2022","unstructured":"Huang IH, Chung WH, Wu PC, Chen CB. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review. Front Immunol. 2022;13:1068260.","journal-title":"Front Immunol"},{"key":"2692_CR8","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu X, Li J, Fu M, Zhao X, Wang W. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6:402.","journal-title":"Signal Transduct Target Ther"},{"key":"2692_CR9","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/s42003-021-01846-3","volume":"4","author":"JG Barcia Dur\u00e1n","year":"2021","unstructured":"Barcia Dur\u00e1n JG, Lu T, Houghton S, Geng F, Schreiner R, Xiang J, et al. Endothelial Jak3 expression enhances pro-hematopoietic angiocrine function in mice. Commun biology. 2021;4:406.","journal-title":"Commun biology"},{"key":"2692_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3389\/fendo.2017.00071","volume":"8","author":"R Ferrao","year":"2017","unstructured":"Ferrao R, Lupardus PJ. The Janus Kinase (JAK) FERM and SH2 Domains: Bringing Specificity to JAK-Receptor Interactions. Front Endocrinol (Lausanne). 2017;8:71.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2692_CR11","first-page":"163","volume-title":"Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation","author":"CR Glassman","year":"2022","unstructured":"Glassman CR, Tsutsumi N, Saxton RA, Lupardus PJ, Jude KM, Garcia KC. Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation. Volume 376. New York, N.Y.): Science; 2022. pp. 163\u20139."},{"key":"2692_CR12","doi-asserted-by":"publisher","first-page":"998","DOI":"10.4049\/jimmunol.180.2.998","volume":"180","author":"S Haan","year":"2008","unstructured":"Haan S, Margue C, Engrand A, Rolvering C, Schmitz-Van de Leur H, Heinrich PC, et al. Dual role of the Jak1 FERM and kinase domains in cytokine receptor binding and in stimulation-dependent Jak activation. J Immunol (Baltimore Md : 1950). 2008;180:998\u20131007.","journal-title":"J Immunol (Baltimore Md : 1950)"},{"key":"2692_CR13","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1002\/pro.3519","volume":"27","author":"R Morris","year":"2018","unstructured":"Morris R, Kershaw NJ, Babon JJ. The molecular details of cytokine signaling via the JAK\/STAT pathway. Protein Sci. 2018;27:1984\u20132009.","journal-title":"Protein Sci"},{"key":"2692_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4049\/jimmunol.1401867","volume":"194","author":"AV Villarino","year":"2015","unstructured":"Villarino AV, Kanno Y, Ferdinand JR, O\u2019Shea JJ. Mechanisms of Jak\/STAT signaling in immunity and disease. J Immunol. 2015;194:21\u20137.","journal-title":"J Immunol"},{"key":"2692_CR15","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1182\/blood.2023022260","volume":"143","author":"W Liu","year":"2024","unstructured":"Liu W, Pircher J, Schuermans A, Ul Ain Q, Zhang Z, Honigberg MC, et al. Jak2 V617F clonal hematopoiesis promotes arterial thrombosis via platelet activation and cross talk. Blood. 2024;143:1539\u201350.","journal-title":"Blood"},{"key":"2692_CR16","doi-asserted-by":"crossref","unstructured":"Perner F, Perner C, Ernst T, Heidel FH. Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation. Cells. 2019;8:854.","DOI":"10.3390\/cells8080854"},{"key":"2692_CR17","doi-asserted-by":"publisher","first-page":"eadf1329","DOI":"10.1126\/science.adf1329","volume":"384","author":"D Mathew","year":"2024","unstructured":"Mathew D, Marmarelis ME, Foley C, Bauml JM, Ye D, Ghinnagow R, et al. Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients. Science. 2024;384:eadf1329.","journal-title":"Science"},{"key":"2692_CR18","doi-asserted-by":"crossref","unstructured":"Liongue C, Ratnayake T, Basheer F, Ward AC. Janus Kinase 3 (JAK3): A Critical Conserved Node in Immunity Disrupted in Immune Cell Cancer and Immunodeficiency. Int J Mol Sci. 2024;25:2977.","DOI":"10.3390\/ijms25052977"},{"key":"2692_CR19","doi-asserted-by":"publisher","first-page":"5373","DOI":"10.2147\/JIR.S380686","volume":"15","author":"L Shang","year":"2022","unstructured":"Shang L, Cao J, Zhao S, Zhang J, He Y. TYK2 in Immune Responses and Treatment of Psoriasis. J Inflamm Res. 2022;15:5373\u201385.","journal-title":"J Inflamm Res"},{"key":"2692_CR20","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0092-8674(00)81277-5","volume":"84","author":"JN Ihle","year":"1996","unstructured":"Ihle JN. STATs: signal transducers and activators of transcription. Cell. 1996;84:331\u20134.","journal-title":"Cell"},{"key":"2692_CR21","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/j.0959-9673.2003.00363.x","volume":"84","author":"A Stephanou","year":"2003","unstructured":"Stephanou A, Latchman DS. STAT-1: a novel regulator of apoptosis. Int J Exp Pathol. 2003;84:239\u201344.","journal-title":"Int J Exp Pathol"},{"key":"2692_CR22","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.cellsig.2006.09.003","volume":"19","author":"HS Kim","year":"2007","unstructured":"Kim HS, Lee MS. STAT1 as a key modulator of cell death. Cell Signal. 2007;19:454\u201365.","journal-title":"Cell Signal"},{"key":"2692_CR23","doi-asserted-by":"crossref","unstructured":"Tolomeo M, Cavalli A, Cascio A. STAT1 and Its Crucial Role in the Control of Viral Infections. Int J Mol Sci. 2022;23:4095.","DOI":"10.3390\/ijms23084095"},{"key":"2692_CR24","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1089\/jir.2022.0117","volume":"42","author":"P Duodu","year":"2022","unstructured":"Duodu P, Sosa G, Canar J, Chhugani O, Gamero AM. Exposing the Two Contrasting Faces of STAT2 in Inflammation. J Interferon Cytokine Res. 2022;42:467\u201381.","journal-title":"J Interferon Cytokine Res"},{"key":"2692_CR25","first-page":"e23633","volume":"2","author":"FZ Chowdhury","year":"2013","unstructured":"Chowdhury FZ, Farrar JD. STAT2: A shape-shifting anti-viral super STAT. Jakstat. 2013;2:e23633.","journal-title":"Jakstat"},{"key":"2692_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13046-024-02949-5","volume":"43","author":"Y Hu","year":"2024","unstructured":"Hu Y, Dong Z, Liu K. Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery. J Exp Clin Cancer Res. 2024;43:23.","journal-title":"J Exp Clin Cancer Res"},{"key":"2692_CR27","doi-asserted-by":"publisher","first-page":"106311","DOI":"10.1016\/j.phrs.2022.106311","volume":"182","author":"M Sadrkhanloo","year":"2022","unstructured":"Sadrkhanloo M, Entezari M, Orouei S, Ghollasi M, Fathi N, Rezaei S, et al. STAT3-EMT axis in tumors: Modulation of cancer metastasis, stemness and therapy response. Pharmacol Res. 2022;182:106311.","journal-title":"Pharmacol Res"},{"key":"2692_CR28","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.7150\/ijbs.41852","volume":"16","author":"C Yang","year":"2020","unstructured":"Yang C, Mai H, Peng J, Zhou B, Hou J, Jiang D. STAT4: an immunoregulator contributing to diverse human diseases. Int J Biol Sci. 2020;16:1575\u201385.","journal-title":"Int J Biol Sci"},{"key":"2692_CR29","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1128\/MCB.20.1.389-401.2000","volume":"20","author":"E Soldaini","year":"2000","unstructured":"Soldaini E, John S, Moro S, Bollenbacher J, Schindler U, Leonard WJ. DNA binding site selection of dimeric and tetrameric Stat5 proteins reveals a large repertoire of divergent tetrameric Stat5a binding sites. Mol Cell Biol. 2000;20:389\u2013401.","journal-title":"Mol Cell Biol"},{"key":"2692_CR30","doi-asserted-by":"publisher","first-page":"1025373","DOI":"10.3389\/fimmu.2022.1025373","volume":"13","author":"MR Smith","year":"2022","unstructured":"Smith MR, Satter LRF, Vargas-Hern\u00e1ndez A. STAT5b: A master regulator of key biological pathways. Front Immunol. 2022;13:1025373.","journal-title":"Front Immunol"},{"key":"2692_CR31","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1101\/gad.14.2.232","volume":"14","author":"M Kieslinger","year":"2000","unstructured":"Kieslinger M, Woldman I, Moriggl R, Hofmann J, Marine JC, Ihle JN, et al. Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation. Genes Dev. 2000;14:232\u201344.","journal-title":"Genes Dev"},{"key":"2692_CR32","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1084\/jem.20011682","volume":"196","author":"K Suzuki","year":"2002","unstructured":"Suzuki K, Nakajima H, Kagami S, Suto A, Ikeda K, Hirose K, et al. Proteolytic processing of Stat6 signaling in mast cells as a negative regulatory mechanism. J Exp Med. 2002;196:27\u201338.","journal-title":"J Exp Med"},{"key":"2692_CR33","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12026-011-8205-2","volume":"50","author":"S Goenka","year":"2011","unstructured":"Goenka S, Kaplan MH. Transcriptional regulation by STAT6. Immunol Res. 2011;50:87\u201396.","journal-title":"Immunol Res"},{"key":"2692_CR34","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.cell.2011.09.022","volume":"147","author":"H Chen","year":"2011","unstructured":"Chen H, Sun H, You F, Sun W, Zhou X, Chen L, et al. Activation of STAT6 by STING is critical for antiviral innate immunity. Cell. 2011;147:436\u201346.","journal-title":"Cell"},{"key":"2692_CR35","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/1098-2264(2000)9999:9999<1::AID-GCC1089>3.0.CO;2-1","volume":"30","author":"H Van Limbergen","year":"2001","unstructured":"Van Limbergen H, Beverloo HB, van Drunen E, Janssens A, H\u00e4hlen K, Poppe B, et al. Molecular cytogenetic and clinical findings in ETV6\/ABL1-positive leukemia. Genes Chromosomes Cancer. 2001;30:274\u201382.","journal-title":"Genes Chromosomes Cancer"},{"key":"2692_CR36","doi-asserted-by":"publisher","first-page":"4849","DOI":"10.1182\/blood-2004-12-4897","volume":"105","author":"K De Keersmaecker","year":"2005","unstructured":"De Keersmaecker K, Graux C, Odero MD, Mentens N, Somers R, Maertens J, et al. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). Blood. 2005;105:4849\u201352.","journal-title":"Blood"},{"key":"2692_CR37","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/ng1425","volume":"36","author":"C Graux","year":"2004","unstructured":"Graux C, Cools J, Melotte C, Quentmeier H, Ferrando A, Levine R, et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet. 2004;36:1084\u20139.","journal-title":"Nat Genet"},{"key":"2692_CR38","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","volume":"371","author":"KG Roberts","year":"2014","unstructured":"Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371:1005\u201315.","journal-title":"N Engl J Med"},{"key":"2692_CR39","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1084\/jem.174.4.867","volume":"174","author":"B Tycko","year":"1991","unstructured":"Tycko B, Smith SD, Sklar J. Chromosomal translocations joining LCK and TCRB loci in human T cell leukemia. J Exp Med. 1991;174:867\u201373.","journal-title":"J Exp Med"},{"key":"2692_CR40","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1182\/blood-2004-01-0168","volume":"104","author":"E Paietta","year":"2004","unstructured":"Paietta E, Ferrando AA, Neuberg D, Bennett JM, Racevskis J, Lazarus H, et al. Activating FLT3 mutations in CD117\/KIT(+) T-cell acute lymphoblastic leukemias. Blood. 2004;104:558\u201360.","journal-title":"Blood"},{"key":"2692_CR41","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.bbrc.2006.05.173","volume":"346","author":"S Tenhumberg","year":"2006","unstructured":"Tenhumberg S, Schuster B, Zhu L, Kovaleva M, Scheller J, Kallen KJ, et al. gp130 dimerization in the absence of ligand: preformed cytokine receptor complexes. Biochem Biophys Res Commun. 2006;346:649\u201357.","journal-title":"Biochem Biophys Res Commun"},{"key":"2692_CR42","doi-asserted-by":"publisher","first-page":"13303","DOI":"10.1074\/jbc.270.22.13303","volume":"270","author":"JH Naismith","year":"1995","unstructured":"Naismith JH, Devine TQ, Brandhuber BJ, Sprang SR. Crystallographic evidence for dimerization of unliganded tumor necrosis factor receptor. J Biol Chem. 1995;270:13303\u20137.","journal-title":"J Biol Chem"},{"key":"2692_CR43","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.bbrc.2005.11.182","volume":"340","author":"CD Krause","year":"2006","unstructured":"Krause CD, Mei E, Mirochnitchenko O, Lavnikova N, Xie J, Jia Y, et al. Interactions among the components of the interleukin-10 receptor complex. Biochem Biophys Res Commun. 2006;340:377\u201385.","journal-title":"Biochem Biophys Res Commun"},{"key":"2692_CR44","doi-asserted-by":"crossref","unstructured":"Kramer JM, Yi L, Shen F, Maitra A, Jiao X, Jin T et al. Evidence for ligand-independent multimerization of the IL-17 receptor. Journal of immunology (Baltimore, Md.: 1950). 2006;176:711-715.","DOI":"10.4049\/jimmunol.176.2.711"},{"key":"2692_CR45","first-page":"990","volume-title":"Erythropoietin receptor activation by a ligand-induced conformation change","author":"I Remy","year":"1999","unstructured":"Remy I, Wilson IA, Michnick SW. Erythropoietin receptor activation by a ligand-induced conformation change. Volume 283. New York, N.Y.): Science; 1999. pp. 990\u20133."},{"key":"2692_CR46","first-page":"987","volume-title":"Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation","author":"O Livnah","year":"1999","unstructured":"Livnah O, Stura EA, Middleton SA, Johnson DL, Jolliffe LK, Wilson IA. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Volume 283. New York, N.Y.): Science; 1999. pp. 987\u201390."},{"key":"2692_CR47","first-page":"1249783","volume-title":"Mechanism of activation of protein kinase JAK2 by the growth hormone receptor","author":"AJ Brooks","year":"2014","unstructured":"Brooks AJ, Dai W, O\u2019Mara ML, Abankwa D, Chhabra Y, Pelekanos RA, et al. Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. Volume 344. New York, N.Y.): Science; 2014. p. 1249783."},{"key":"2692_CR48","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1101\/gad.9.8.984","volume":"9","author":"CM Horvath","year":"1995","unstructured":"Horvath CM, Wen Z, Darnell JE Jr. A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain. Genes Dev. 1995;9:984\u201394.","journal-title":"Genes Dev"},{"key":"2692_CR49","doi-asserted-by":"publisher","first-page":"30264","DOI":"10.1074\/jbc.270.51.30264","volume":"270","author":"DC Look","year":"1995","unstructured":"Look DC, Pelletier MR, Tidwell RM, Roswit WT, Holtzman MJ. Stat1 depends on transcriptional synergy with Sp1. J Biol Chem. 1995;270:30264\u20137.","journal-title":"J Biol Chem"},{"key":"2692_CR50","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1128\/MCB.15.5.2558","volume":"15","author":"AS Neish","year":"1995","unstructured":"Neish AS, Read MA, Thanos D, Pine R, Maniatis T, Collins T. Endothelial interferon regulatory factor 1 cooperates with NF-kappa B as a transcriptional activator of vascular cell adhesion molecule 1. Mol Cell Biol. 1995;15:2558\u201369.","journal-title":"Mol Cell Biol"},{"key":"2692_CR51","doi-asserted-by":"publisher","first-page":"8521","DOI":"10.1073\/pnas.85.22.8521","volume":"85","author":"DS Kessler","year":"1988","unstructured":"Kessler DS, Levy DE, Darnell JE Jr. Two interferon-induced nuclear factors bind a single promoter element in interferon-stimulated genes. Proc Natl Acad Sci U S A. 1988;85:8521\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2692_CR52","doi-asserted-by":"crossref","unstructured":"Kundu G, Ghasemi M, Yim S, Rohil A, Xin C, Ren L, et al. STAT3 Protein-Protein Interaction Analysis Finds P300 as a Regulator of STAT3 and Histone 3 Lysine 27 Acetylation in Pericytes. Biomedicines. 2024;12:2102.","DOI":"10.3390\/biomedicines12092102"},{"key":"2692_CR53","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.smim.2013.12.005","volume":"26","author":"JA Meier","year":"2014","unstructured":"Meier JA, Larner AC. Toward a new STATe: the role of STATs in mitochondrial function. Semin Immunol. 2014;26:20\u20138.","journal-title":"Semin Immunol"},{"key":"2692_CR54","doi-asserted-by":"crossref","unstructured":"Gai L, Zhu Y, Zhang C, Meng X. Targeting Canonical and Non-Canonical STAT Signaling Pathways in Renal Diseases. Cells. 2021;10:1610.","DOI":"10.3390\/cells10071610"},{"key":"2692_CR55","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/s41418-018-0171-y","volume":"26","author":"L Avalle","year":"2019","unstructured":"Avalle L, Camporeale A, Morciano G, Caroccia N, Ghetti E, Orecchia V, et al. STAT3 localizes to the ER, acting as a gatekeeper for ER-mitochondrion Ca(2+) fluxes and apoptotic responses. Cell Death Differ. 2019;26:932\u201342.","journal-title":"Cell Death Differ"},{"key":"2692_CR56","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1073\/pnas.1608576114","volume":"114","author":"C Liu","year":"2017","unstructured":"Liu C, Mei M, Li Q, Roboti P, Pang Q, Ying Z, et al. Loss of the golgin GM130 causes Golgi disruption, Purkinje neuron loss, and ataxia in mice. Proc Natl Acad Sci USA. 2017;114:346\u201351.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2692_CR57","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.canlet.2021.05.035","volume":"516","author":"J Zhang","year":"2021","unstructured":"Zhang J, Zeng Y, Xing Y, Li X, Zhou L, Hu L, et al. Myristoylation-mediated phase separation of EZH2 compartmentalizes STAT3 to promote lung cancer growth. Cancer Lett. 2021;516:84\u201398.","journal-title":"Cancer Lett"},{"key":"2692_CR58","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41392-024-01934-w","volume":"9","author":"Y Lv","year":"2024","unstructured":"Lv Y, Qi J, Babon JJ, Cao L, Fan G, Lang J, et al. The JAK-STAT pathway: from structural biology to cytokine engineering. Signal Transduct Target Ther. 2024;9:221.","journal-title":"Signal Transduct Target Ther"},{"key":"2692_CR59","doi-asserted-by":"publisher","first-page":"e15127","DOI":"10.1002\/advs.202515127","volume":"13","author":"H Mei","year":"2026","unstructured":"Mei H, Wen W, Zhang W, Zhang S, Sun T, Li G, et al. Targeting DESI2 as a Novel Therapeutic Strategy for JAK2-Mutant Leukemias. Adv Sci (Weinh). 2026;13:e15127.","journal-title":"Adv Sci (Weinh)"},{"key":"2692_CR60","doi-asserted-by":"publisher","first-page":"151452","DOI":"10.1016\/j.ejcb.2024.151452","volume":"103","author":"S Yao","year":"2024","unstructured":"Yao S, Zhu Y, He F, Yuan M, Jiang R, Zhang H, et al. JAK activity regulates mesoderm cell fate by controlling MESP1 expression. Eur J Cell Biol. 2024;103:151452.","journal-title":"Eur J Cell Biol"},{"key":"2692_CR61","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41392-023-01331-9","volume":"8","author":"Q Ding","year":"2023","unstructured":"Ding Q, Hu W, Wang R, Yang Q, Zhu M, Li M, et al. Signaling pathways in rheumatoid arthritis: implications for targeted therapy. Signal Transduct Target Ther. 2023;8:68.","journal-title":"Signal Transduct Target Ther"},{"key":"2692_CR62","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/jlb.66.4.588","volume":"66","author":"WS Alexander","year":"1999","unstructured":"Alexander WS, Starr R, Metcalf D, Nicholson SE, Farley A, Elefanty AG, et al. Suppressors of cytokine signaling (SOCS): negative regulators of signal transduction. J Leukoc Biol. 1999;66:588\u201392.","journal-title":"J Leukoc Biol"},{"issue":"Pt 16","key":"2692_CR63","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1242\/jcs.113.16.2813","volume":"113","author":"DL Krebs","year":"2000","unstructured":"Krebs DL, Hilton DJ. SOCS: physiological suppressors of cytokine signaling. J Cell Sci. 2000;113(Pt 16):2813\u20139.","journal-title":"J Cell Sci"},{"key":"2692_CR64","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1038\/s41467-018-04013-1","volume":"9","author":"NPD Liau","year":"2018","unstructured":"Liau NPD, Laktyushin A, Lucet IS, Murphy JM, Yao S, Whitlock E, et al. The molecular basis of JAK\/STAT inhibition by SOCS1. Nat Commun. 2018;9:1558.","journal-title":"Nat Commun"},{"key":"2692_CR65","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nsmb.2519","volume":"20","author":"NJ Kershaw","year":"2013","unstructured":"Kershaw NJ, Murphy JM, Liau NP, Varghese LN, Laktyushin A, Whitlock EL, et al. SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by direct kinase inhibition. Nat Struct Mol Biol. 2013;20:469\u201376.","journal-title":"Nat Struct Mol Biol"},{"key":"2692_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/08977194.2013.877005","volume":"32","author":"NJ Kershaw","year":"2014","unstructured":"Kershaw NJ, Laktyushin A, Nicola NA, Babon JJ. Reconstruction of an active SOCS3-based E3 ubiquitin ligase complex in vitro: identification of the active components and JAK2 and gp130 as substrates. Growth Factors. 2014;32:1\u201310.","journal-title":"Growth Factors"},{"key":"2692_CR67","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jmb.2009.01.024","volume":"387","author":"JJ Babon","year":"2009","unstructured":"Babon JJ, Sabo JK, Zhang JG, Nicola NA, Norton RS. The SOCS box encodes a hierarchy of affinities for Cullin5: implications for ubiquitin ligase formation and cytokine signalling suppression. J Mol Biol. 2009;387:162\u201374.","journal-title":"J Mol Biol"},{"key":"2692_CR68","doi-asserted-by":"publisher","first-page":"5754","DOI":"10.1523\/JNEUROSCI.5007-09.2010","volume":"30","author":"E Dominguez","year":"2010","unstructured":"Dominguez E, Mauborgne A, Mallet J, Desclaux M, Pohl M. SOCS3-mediated blockade of JAK\/STAT3 signaling pathway reveals its major contribution to spinal cord neuroinflammation and mechanical allodynia after peripheral nerve injury. J Neurosci. 2010;30:5754\u201366.","journal-title":"J Neurosci"},{"key":"2692_CR69","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3389\/fimmu.2014.00058","volume":"5","author":"B Carow","year":"2014","unstructured":"Carow B, Rottenberg ME. SOCS3, a Major Regulator of Infection and Inflammation. Front Immunol. 2014;5:58.","journal-title":"Front Immunol"},{"key":"2692_CR70","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood.V89.9.3148","volume":"89","author":"A Matsumoto","year":"1997","unstructured":"Matsumoto A, Masuhara M, Mitsui K, Yokouchi M, Ohtsubo M, Misawa H, et al. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood. 1997;89:3148\u201354.","journal-title":"Blood"},{"key":"2692_CR71","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1073\/pnas.0307598100","volume":"101","author":"J Long","year":"2004","unstructured":"Long J, Wang G, Matsuura I, He D, Liu F. Activation of Smad transcriptional activity by protein inhibitor of activated STAT3 (PIAS3). Proc Natl Acad Sci U S A. 2004;101:99\u2013104.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2692_CR72","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/S0002-9440(10)63403-7","volume":"165","author":"CV Clevenger","year":"2004","unstructured":"Clevenger CV. Roles and regulation of stat family transcription factors in human breast cancer. Am J Pathol. 2004;165:1449\u201360.","journal-title":"Am J Pathol"},{"key":"2692_CR73","doi-asserted-by":"crossref","unstructured":"Bao Q, Zhang B, Suo Y, Liu C, Yang Q, Zhang K, et al. Intermittent hypoxia mediated by TSP1 dependent on STAT3 induces cardiac fibroblast activation and cardiac fibrosis. Elife. 2020;9:e49923.","DOI":"10.7554\/eLife.49923"},{"key":"2692_CR74","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.1073\/pnas.95.7.3845","volume":"95","author":"TS Migone","year":"1998","unstructured":"Migone TS, Cacalano NA, Taylor N, Yi T, Waldmann TA, Johnston JA. Recruitment of SH2-containing protein tyrosine phosphatase SHP-1 to the interleukin 2 receptor; loss of SHP-1 expression in human T-lymphotropic virus type I-transformed T cells. Proc Natl Acad Sci U S A. 1998;95:3845\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2692_CR75","doi-asserted-by":"publisher","first-page":"6985","DOI":"10.1128\/MCB.16.12.6985","volume":"16","author":"H Jiao","year":"1996","unstructured":"Jiao H, Berrada K, Yang W, Tabrizi M, Platanias LC, Yi T. Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1. Mol Cell Biol. 1996;16:6985\u201392.","journal-title":"Mol Cell Biol"},{"key":"2692_CR76","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1128\/MCB.19.3.2416","volume":"19","author":"M You","year":"1999","unstructured":"You M, Yu DH, Feng GS. Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak\/STAT pathway. Mol Cell Biol. 1999;19:2416\u201324.","journal-title":"Mol Cell Biol"},{"key":"2692_CR77","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779\u201390.","journal-title":"N Engl J Med"},{"key":"2692_CR78","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jaci.2024.09.020","volume":"155","author":"S Samra","year":"2025","unstructured":"Samra S, Bergerson JRE, Freeman AF, Turvey SE. JAK-STAT signaling pathway, immunodeficiency, inflammation, immune dysregulation, and inborn errors of immunity. J Allergy Clin Immunol. 2025;155:357\u201367.","journal-title":"J Allergy Clin Immunol"},{"key":"2692_CR79","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1038\/s41467-018-04521-0","volume":"9","author":"J Klammt","year":"2018","unstructured":"Klammt J, Neumann D, Gevers EF, Andrew SF, Schwartz ID, Rockstroh D, et al. Dominant-negative STAT5B mutations cause growth hormone insensitivity with short stature and mild immune dysregulation. Nat Commun. 2018;9:2105.","journal-title":"Nat Commun"},{"key":"2692_CR80","doi-asserted-by":"publisher","first-page":"1385190","DOI":"10.3389\/fimmu.2024.1385190","volume":"15","author":"J K\u00f6rholz","year":"2024","unstructured":"K\u00f6rholz J, Chen LS, Strauss T, Schuetz C, Dalpke AH. One gene to rule them all - clinical perspectives of a potent suppressor of cytokine signaling - SOCS1. Front Immunol. 2024;15:1385190.","journal-title":"Front Immunol"},{"key":"2692_CR81","doi-asserted-by":"publisher","first-page":"680334","DOI":"10.3389\/fimmu.2021.680334","volume":"12","author":"J K\u00f6rholz","year":"2021","unstructured":"K\u00f6rholz J, Gabrielyan A, Sowerby JM, Boschann F, Chen LS, Paul D, et al. One Gene, Many Facets: Multiple Immune Pathway Dysregulation in SOCS1 Haploinsufficiency. Front Immunol. 2021;12:680334.","journal-title":"Front Immunol"},{"key":"2692_CR82","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41375-018-0342-3","volume":"33","author":"NCP Cross","year":"2019","unstructured":"Cross NCP, Hoade Y, Tapper WJ, Carreno-Tarragona G, Fanelli T, Jawhar M, et al. Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia. Leukemia. 2019;33:415\u201325.","journal-title":"Leukemia"},{"key":"2692_CR83","first-page":"1825","volume":"109","author":"CC Yin","year":"2024","unstructured":"Yin CC, Tam W, Walker SM, Kaur A, Ouseph MM, Xie W, et al. STAT5B mutations in myeloid neoplasms differ by disease subtypes but characterize a subset of chronic myeloid neoplasms with eosinophilia and\/or basophilia. Haematologica. 2024;109:1825\u201335.","journal-title":"Haematologica"},{"key":"2692_CR84","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.toxlet.2013.12.023","volume":"225","author":"C Cheng","year":"2014","unstructured":"Cheng C, Huang C, Ma TT, Bian EB, He Y, Zhang L, et al. SOCS1 hypermethylation mediated by DNMT1 is associated with lipopolysaccharide-induced inflammatory cytokines in macrophages. Toxicol Lett. 2014;225:488\u201397.","journal-title":"Toxicol Lett"},{"key":"2692_CR85","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/s41416-025-02969-8","volume":"132","author":"HY Lin","year":"2025","unstructured":"Lin HY, Jeon AJ, Chen K, Lee CJM, Wu L, Chong SL, et al. The epigenetic basis of hepatocellular carcinoma - mechanisms and potential directions for biomarkers and therapeutics. Br J Cancer. 2025;132:869\u201387.","journal-title":"Br J Cancer"},{"key":"2692_CR86","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/ng0501-29","volume":"28","author":"H Yoshikawa","year":"2001","unstructured":"Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, et al. SOCS-1, a negative regulator of the JAK\/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet. 2001;28:29\u201335.","journal-title":"Nat Genet"},{"key":"2692_CR87","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12935-024-03322-4","volume":"24","author":"L Lou","year":"2024","unstructured":"Lou L, Deng T, Yuan Q, Wang L, Wang Z, Li X. Targeted silencing of SOCS1 by DNMT1 promotes stemness of human liver cancer stem-like cells. Cancer Cell Int. 2024;24:206.","journal-title":"Cancer Cell Int"},{"key":"2692_CR88","doi-asserted-by":"publisher","first-page":"114152","DOI":"10.1016\/j.yexcr.2024.114152","volume":"441","author":"P Lei","year":"2024","unstructured":"Lei P, Wang X, Qu X, Qi R, Chen D, Chang Y. The expression of SOCS1 is regulated by promoter DNA methylation and is associated with mitochondria-mediated apoptosis of T-2 induced chondrocytes. Exp Cell Res. 2024;441:114152.","journal-title":"Exp Cell Res"},{"key":"2692_CR89","doi-asserted-by":"publisher","first-page":"6699","DOI":"10.1038\/sj.onc.1208818","volume":"24","author":"A Weber","year":"2005","unstructured":"Weber A, Hengge UR, Bardenheuer W, Tischoff I, Sommerer F, Markwarth A, et al. SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. Oncogene. 2005;24:6699\u2013708.","journal-title":"Oncogene"},{"key":"2692_CR90","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/bjh.18694","volume":"201","author":"A Lahera","year":"2023","unstructured":"Lahera A, L\u00f3pez-Nieva P, Alarc\u00f3n H, Mar\u00edn-Rubio JL, Cobos-Fern\u00e1ndez M, Fern\u00e1ndez-Navarro P, et al. SOCS3 deregulation contributes to aberrant activation of the JAK\/STAT pathway in precursor T-cell neoplasms. Br J Haematol. 2023;201:718\u201324.","journal-title":"Br J Haematol"},{"key":"2692_CR91","doi-asserted-by":"publisher","first-page":"14133","DOI":"10.1073\/pnas.2232790100","volume":"100","author":"B He","year":"2003","unstructured":"He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, et al. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci U S A. 2003;100:14133\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2692_CR92","doi-asserted-by":"publisher","first-page":"8470","DOI":"10.1038\/ncomms9470","volume":"6","author":"MJ Kiel","year":"2015","unstructured":"Kiel MJ, Sahasrabuddhe AA, Rolland DCM, Velusamy T, Chung F, Schaller M, et al. Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in S\u00e9zary syndrome. Nat Commun. 2015;6:8470.","journal-title":"Nat Commun"},{"key":"2692_CR93","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1182\/blood.2019004256","volume":"139","author":"CP Tensen","year":"2022","unstructured":"Tensen CP, Quint KD, Vermeer MH. Genetic and epigenetic insights into cutaneous T-cell lymphoma. Blood. 2022;139:15\u201333.","journal-title":"Blood"},{"key":"2692_CR94","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ccr.2010.12.020","volume":"19","author":"F Liu","year":"2011","unstructured":"Liu F, Zhao X, Perna F, Wang L, Koppikar P, Abdel-Wahab O, et al. JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell. 2011;19:283\u201394.","journal-title":"Cancer Cell"},{"key":"2692_CR95","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/nature08448","volume":"461","author":"MA Dawson","year":"2009","unstructured":"Dawson MA, Bannister AJ, G\u00f6ttgens B, Foster SD, Bartke T, Green AR, et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature. 2009;461:819\u201322.","journal-title":"Nature"},{"key":"2692_CR96","first-page":"744","volume":"55","author":"M Cheng","year":"2024","unstructured":"Cheng M, Jia L, Xue Z, Yang T, Zhou X, Zhao G. [H3K27me3 Expression Level and Its Epigenetic Regulation Mechanisms in Th17 Cell Differentiation in Patients With Ankylosing Spondylitis]. Sichuan da xue xue bao Yi xue ban = J Sichuan Univ Med Sci Ed. 2024;55:744\u20138.","journal-title":"Sichuan da xue xue bao Yi xue ban = J Sichuan Univ Med Sci Ed"},{"key":"2692_CR97","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s41232-018-0078-5","volume":"38","author":"S Sumitomo","year":"2018","unstructured":"Sumitomo S, Nagafuchi Y, Tsuchida Y, Tsuchiya H, Ota M, Ishigaki K, et al. Transcriptome analysis of peripheral blood from patients with rheumatoid arthritis: a systematic review. Inflamm regeneration. 2018;38:21.","journal-title":"Inflamm regeneration"},{"key":"2692_CR98","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1124\/pharmrev.122.000612","volume":"75","author":"AM Mustafa","year":"2023","unstructured":"Mustafa AM, Kr\u00e4mer OH. Pharmacological Modulation of the Crosstalk between Aberrant Janus Kinase Signaling and Epigenetic Modifiers of the Histone Deacetylase Family to Treat Cancer. Pharmacol Rev. 2023;75:35\u201361.","journal-title":"Pharmacol Rev"},{"key":"2692_CR99","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/13543784.2020.1761323","volume":"29","author":"HT Chifotides","year":"2020","unstructured":"Chifotides HT, Bose P, Verstovsek S. Givinostat: an emerging treatment for polycythemia vera. Expert Opin Investig Drugs. 2020;29:525\u201336.","journal-title":"Expert Opin Investig Drugs"},{"key":"2692_CR100","doi-asserted-by":"publisher","first-page":"41631","DOI":"10.1038\/s41598-025-25642-9","volume":"15","author":"L Luo","year":"2025","unstructured":"Luo L, Zhang K, Mu S, Liu S, Xiao W, Liu X. Inhibition of microRNA-155 regulates gastric mucosal barrier repair and inflammation by targeting SOCS1 for the treatment of acute gastritis. Sci Rep. 2025;15:41631.","journal-title":"Sci Rep"},{"key":"2692_CR101","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1042\/BCJ20240626","volume":"482","author":"Q Li","year":"2025","unstructured":"Li Q, Bai Y, Cavender SM, Miao Y, Nguele Meke F, Lasse-Opsahl EL, et al. The PRL2 phosphatase up-regulates miR-21 through activation of the JAK2\/STAT3 pathway to down-regulate the PTEN tumor suppressor. Biochem J. 2025;482:341\u201356.","journal-title":"Biochem J"},{"key":"2692_CR102","doi-asserted-by":"crossref","unstructured":"Ali SR, Jordan M, Nagarajan P, Amit M. Nerve Density and Neuronal Biomarkers in Cancer. Cancers (Basel). 2022;14:4817.","DOI":"10.3390\/cancers14194817"},{"key":"2692_CR103","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1007\/s10571-021-01091-6","volume":"42","author":"J Xu","year":"2022","unstructured":"Xu J, Zheng Y, Wang L, Liu Y, Wang X, Li Y, et al. miR-124: A Promising Therapeutic Target for Central Nervous System Injuries and Diseases. Cell Mol Neurobiol. 2022;42:2031\u201353.","journal-title":"Cell Mol Neurobiol"},{"key":"2692_CR104","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1016\/j.apsb.2025.02.034","volume":"15","author":"S Li","year":"2025","unstructured":"Li S, Liu Y, Yin X, Yang Y, Liu X, Qiu J, et al. Identification of a JAK-STAT-miR155HG positive feedback loop in regulating natural killer (NK) cells proliferation and effector functions. Acta Pharm Sin B. 2025;15:1922\u201337.","journal-title":"Acta Pharm Sin B"},{"key":"2692_CR105","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s10571-022-01200-z","volume":"43","author":"SH Rastegar-Moghaddam","year":"2023","unstructured":"Rastegar-Moghaddam SH, Ebrahimzadeh-Bideskan A, Shahba S, Malvandi AM, Mohammadipour A. Roles of the miR-155 in Neuroinflammation and Neurological Disorders: A Potent Biological and Therapeutic Target. Cell Mol Neurobiol. 2023;43:455\u201367.","journal-title":"Cell Mol Neurobiol"},{"key":"2692_CR106","doi-asserted-by":"crossref","unstructured":"Zhang P, Li Z, Yang G. Silencing of ISLR inhibits tumour progression and glycolysis by inactivating the IL\u20136\/JAK\/STAT3 pathway in non\u2013small cell lung cancer. Int J Mol Med. 2021;48:222.","DOI":"10.3892\/ijmm.2021.5055"},{"key":"2692_CR107","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/0092-8674(93)90414-L","volume":"74","author":"BA Witthuhn","year":"1993","unstructured":"Witthuhn BA, Quelle FW, Silvennoinen O, Yi T, Tang B, Miura O, et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell. 1993;74:227\u201336.","journal-title":"Cell"},{"key":"2692_CR108","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1172\/JCI25227","volume":"116","author":"MP Menon","year":"2006","unstructured":"Menon MP, Karur V, Bogacheva O, Bogachev O, Cuetara B, Wojchowski DM. Signals for stress erythropoiesis are integrated via an erythropoietin receptor-phosphotyrosine-343-Stat5 axis. J Clin Invest. 2006;116:683\u201394.","journal-title":"J Clin Invest"},{"key":"2692_CR109","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1182\/blood.V98.12.3261","volume":"98","author":"M Socolovsky","year":"2001","unstructured":"Socolovsky M, Nam H, Fleming MD, Haase VH, Brugnara C, Lodish HF. Ineffective erythropoiesis in Stat5a(-\/-)5b(-\/-) mice due to decreased survival of early erythroblasts. Blood. 2001;98:3261\u201373.","journal-title":"Blood"},{"key":"2692_CR110","doi-asserted-by":"publisher","first-page":"1336102","DOI":"10.3389\/fphar.2024.1336102","volume":"15","author":"H Jiang","year":"2024","unstructured":"Jiang H, Yang J, Li T, Wang X, Fan Z, Ye Q, et al. JAK\/STAT3 signaling in cardiac fibrosis: a promising therapeutic target. Front Pharmacol. 2024;15:1336102.","journal-title":"Front Pharmacol"},{"key":"2692_CR111","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.yjmcc.2025.07.017","volume":"207","author":"A Subramani","year":"2025","unstructured":"Subramani A, Essandoh K, Young MY, Marino FH, Teuber JP, Wagner KU, et al. Cardiomyocyte Janus kinase 1 (JAK1) signaling is required for cardiac homeostasis and cytokine-dependent activation of STAT3. J Mol Cell Cardiol. 2025;207:13\u201323.","journal-title":"J Mol Cell Cardiol"},{"key":"2692_CR112","doi-asserted-by":"publisher","first-page":"523","DOI":"10.2147\/ITT.S485670","volume":"14","author":"S Parveen","year":"2025","unstructured":"Parveen S, Fatma M, Mir SS, Dermime S, Uddin S. JAK-STAT Signaling in Autoimmunity and Cancer. Immunotargets Ther. 2025;14:523\u201354.","journal-title":"Immunotargets Ther"},{"key":"2692_CR113","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","volume":"9","author":"Q Guo","year":"2024","unstructured":"Guo Q, Jin Y, Chen X, Ye X, Shen X, Lin M, et al. NF-\u03baB in biology and targeted therapy: new insights and translational implications. Signal Transduct Target Ther. 2024;9:53.","journal-title":"Signal Transduct Target Ther"},{"key":"2692_CR114","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1016\/j.molimm.2007.02.022","volume":"44","author":"EY So","year":"2007","unstructured":"So EY, Oh J, Jang JY, Kim JH, Lee CE. Ras\/Erk pathway positively regulates Jak1\/STAT6 activity and IL-4 gene expression in Jurkat T cells. Mol Immunol. 2007;44:3416\u201326.","journal-title":"Mol Immunol"},{"issue":"Suppl 2","key":"2692_CR115","doi-asserted-by":"publisher","first-page":"S307","DOI":"10.1016\/j.clml.2013.07.011","volume":"13","author":"N Bartalucci","year":"2013","unstructured":"Bartalucci N, Guglielmelli P, Vannucchi AM. Rationale for targeting the PI3K\/Akt\/mTOR pathway in myeloproliferative neoplasms. Clin Lymphoma Myeloma Leuk. 2013;13(Suppl 2):S307\u2013309.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2692_CR116","doi-asserted-by":"publisher","first-page":"e14333","DOI":"10.1111\/jfbc.14333","volume":"46","author":"N \u00dcremi\u015f","year":"2022","unstructured":"\u00dcremi\u015f N, \u00dcremi\u015f MM, \u00c7i\u011fremi\u015f Y, Tosun E, Baysar A, T\u00fcrk\u00f6z Y. Cucurbitacin I exhibits anticancer efficacy through induction of apoptosis and modulation of JAK\/STAT3, MAPK\/ERK, and AKT\/mTOR signaling pathways in HepG2 cell line. J Food Biochem. 2022;46:e14333.","journal-title":"J Food Biochem"},{"key":"2692_CR117","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1007\/s10120-021-01186-5","volume":"24","author":"SJ Kim","year":"2021","unstructured":"Kim SJ, Kang HG, Kim K, Kim H, Zetterberg F, Park YS, et al. Crosstalk between WNT and STAT3 is mediated by galectin-3 in tumor progression. Gastric Cancer. 2021;24:1050\u201362.","journal-title":"Gastric Cancer"},{"key":"2692_CR118","doi-asserted-by":"publisher","first-page":"e46892","DOI":"10.1371\/journal.pone.0046892","volume":"7","author":"MA Fragoso","year":"2012","unstructured":"Fragoso MA, Patel AK, Nakamura RE, Yi H, Surapaneni K, Hackam AS. The Wnt\/\u03b2-catenin pathway cross-talks with STAT3 signaling to regulate survival of retinal pigment epithelium cells. PLoS ONE. 2012;7:e46892.","journal-title":"PLoS ONE"},{"key":"2692_CR119","doi-asserted-by":"publisher","first-page":"ra92","DOI":"10.1126\/scisignal.2005411","volume":"7","author":"TJ Phesse","year":"2014","unstructured":"Phesse TJ, Buchert M, Stuart E, Flanagan DJ, Faux M, Afshar-Sterle S, et al. Partial inhibition of gp130-Jak-Stat3 signaling prevents Wnt-\u03b2-catenin-mediated intestinal tumor growth and regeneration. Sci Signal. 2014;7:ra92.","journal-title":"Sci Signal"},{"key":"2692_CR120","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11010-018-3406-9","volume":"451","author":"N Knutti","year":"2019","unstructured":"Knutti N, Huber O, Friedrich K. CD147 (EMMPRIN) controls malignant properties of breast cancer cells by interdependent signaling of Wnt and JAK\/STAT pathways. Mol Cell Biochem. 2019;451:197\u2013209.","journal-title":"Mol Cell Biochem"},{"key":"2692_CR121","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s12032-022-01897-4","volume":"40","author":"B Goker Bagca","year":"2022","unstructured":"Goker Bagca B, Ozates NP, Biray Avci C. Ruxolitinib enhances cytotoxic and apoptotic effects of temozolomide on glioblastoma cells by regulating WNT signaling pathway-related genes. Med Oncol. 2022;40:37.","journal-title":"Med Oncol"},{"key":"2692_CR122","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.ncrna.2024.04.001","volume":"9","author":"AA Farooqi","year":"2024","unstructured":"Farooqi AA, Shepetov AM, Rakhmetova V, Ruslan Z, Almabayeva A, Saussakova S, et al. Interplay between JAK\/STAT pathway and non-coding RNAs in different cancers. Noncoding RNA Res. 2024;9:1009\u201322.","journal-title":"Noncoding RNA Res"},{"key":"2692_CR123","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s13046-020-01769-7","volume":"39","author":"Z Zhao","year":"2020","unstructured":"Zhao Z, Song J, Tang B, Fang S, Zhang D, Zheng L, et al. CircSOD2 induced epigenetic alteration drives hepatocellular carcinoma progression through activating JAK2\/STAT3 signaling pathway. J Exp Clin Cancer Res. 2020;39:259.","journal-title":"J Exp Clin Cancer Res"},{"key":"2692_CR124","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12929-020-00697-0","volume":"28","author":"F Wang","year":"2021","unstructured":"Wang F, Wang X, Li J, Lv P, Han M, Li L, et al. CircNOL10 suppresses breast cancer progression by sponging miR-767-5p to regulate SOCS2\/JAK\/STAT signaling. J Biomed Sci. 2021;28:4.","journal-title":"J Biomed Sci"},{"key":"2692_CR125","doi-asserted-by":"crossref","unstructured":"Peng J, Cui L, Guo M, Liu Y, Jia W, Misuno K, et al. SOX11 Is Regulated by EGFR-STAT3 and Promotes Epithelial-Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma. Cells. 2026;15:84.","DOI":"10.3390\/cells15010084"},{"key":"2692_CR126","doi-asserted-by":"publisher","first-page":"1706270","DOI":"10.3389\/fcimb.2025.1706270","volume":"15","author":"R Gu","year":"2025","unstructured":"Gu R, Zhang H, Xu E, Liu S. The regulatory roles of STAT3 protein in the pathogenesis of viral infections. Front Cell Infect Microbiol. 2025;15:1706270.","journal-title":"Front Cell Infect Microbiol"},{"key":"2692_CR127","doi-asserted-by":"crossref","unstructured":"Valle-Mendiola A, Guti\u00e9rrez-Hoya A, Soto-Cruz I. JAK\/STAT Signaling and Cervical Cancer: From the Cell Surface to the Nucleus. Genes. 2023;14:1141.","DOI":"10.3390\/genes14061141"},{"key":"2692_CR128","doi-asserted-by":"publisher","first-page":"7051","DOI":"10.7150\/thno.73099","volume":"12","author":"S Cai","year":"2022","unstructured":"Cai S, Li N, Bai X, Liu L, Banerjee A, Lavudi K, et al. ERK inactivation enhances stemness of NSCLC cells via promoting Slug-mediated epithelial-to-mesenchymal transition. Theranostics. 2022;12:7051\u201366.","journal-title":"Theranostics"},{"key":"2692_CR129","doi-asserted-by":"crossref","unstructured":"Ali W, Xiao W, Jacobs D, Kajdacsy-Balla A. Survival and Enrichment Analysis of Epithelial-Mesenchymal Transition Genes in Bladder Urothelial Carcinoma. Genes (Basel). 2023;14:1899.","DOI":"10.3390\/genes14101899"},{"key":"2692_CR130","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1080\/15384047.2022.2051158","volume":"23","author":"H Gao","year":"2022","unstructured":"Gao H, Wang W, Li Q. GANT61 suppresses cell survival, invasion and epithelial-mesenchymal transition through inactivating AKT\/mTOR and JAK\/STAT3 pathways in anaplastic thyroid carcinoma. Cancer Biol Ther. 2022;23:369\u201377.","journal-title":"Cancer Biol Ther"},{"key":"2692_CR131","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13046-019-1161-8","volume":"38","author":"M Shen","year":"2019","unstructured":"Shen M, Xu Z, Xu W, Jiang K, Zhang F, Ding Q, et al. Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK\/STAT3\/PD-L1 pathway. J Exp Clin Cancer Res. 2019;38:149.","journal-title":"J Exp Clin Cancer Res"},{"key":"2692_CR132","doi-asserted-by":"crossref","unstructured":"Obeagu EI. Inflammation, immunity, and invasion: the pivotal role of cytokine storms in cervical carcinogenesis. Annals of medicine and surgery (2012). 2026;88:492\u201399.","DOI":"10.1097\/MS9.0000000000004352"},{"key":"2692_CR133","doi-asserted-by":"crossref","unstructured":"Tishler H, Ziman S, Cheng K, Wang K, Sanghvi N, Adler L, et al. Inhibition of Tumor Microenvironment-Driven JAK-STAT Signaling Enhances Response to Arginine Deprivation Therapy in Triple-Negative Breast Cancer. Cells. 2025;15:25.","DOI":"10.3390\/cells15010025"},{"key":"2692_CR134","doi-asserted-by":"publisher","first-page":"ra79","DOI":"10.1126\/scisignal.aaf3273","volume":"9","author":"LR Carpio","year":"2016","unstructured":"Carpio LR, Bradley EW, McGee-Lawrence ME, Weivoda MM, Poston DD, Dudakovic A, et al. Histone deacetylase 3 supports endochondral bone formation by controlling cytokine signaling and matrix remodeling. Sci Signal. 2016;9:ra79.","journal-title":"Sci Signal"},{"key":"2692_CR135","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s00726-023-03285-2","volume":"55","author":"T Rajakumar","year":"2023","unstructured":"Rajakumar T, Pugalendhi P. Allyl isothiocyanate inhibits invasion and angiogenesis in breast cancer via EGFR-mediated JAK-1\/STAT-3 signaling pathway. Amino Acids. 2023;55:981\u201392.","journal-title":"Amino Acids"},{"key":"2692_CR136","doi-asserted-by":"publisher","first-page":"e0248111","DOI":"10.1371\/journal.pone.0248111","volume":"16","author":"H Cao","year":"2021","unstructured":"Cao H, Qiang L, Chen J, Johnson KM, McNiven MA, Razidlo GL. Synergistic metalloproteinase-based remodeling of matrix by pancreatic tumor and stromal cells. PLoS ONE. 2021;16:e0248111.","journal-title":"PLoS ONE"},{"key":"2692_CR137","doi-asserted-by":"publisher","first-page":"1507621","DOI":"10.3389\/fcell.2024.1507621","volume":"12","author":"P Li","year":"2024","unstructured":"Li P, Huang D. Targeting the JAK-STAT pathway in colorectal cancer: mechanisms, clinical implications, and therapeutic potential. Front cell Dev biology. 2024;12:1507621.","journal-title":"Front cell Dev biology"},{"key":"2692_CR138","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1080\/10428194.2017.1324155","volume":"59","author":"Z Cheng","year":"2018","unstructured":"Cheng Z, Fu J, Liu G, Zhang L, Xu Q, Wang SY. Angiogenesis in JAK2 V617F positive myeloproliferative neoplasms and ruxolitinib decrease VEGF, HIF-1 enesis in JAK2 V617F positive cells. Leuk Lymphoma. 2018;59:196\u2013203.","journal-title":"Leuk Lymphoma"},{"key":"2692_CR139","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1530\/JOE-11-0100","volume":"211","author":"Y Lin","year":"2011","unstructured":"Lin Y, Li S, Cao P, Cheng L, Quan M, Jiang S. The effects of recombinant human GH on promoting tumor growth depend on the expression of GH receptor in vivo. J Endocrinol. 2011;211:249\u201356.","journal-title":"J Endocrinol"},{"key":"2692_CR140","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1038\/sj.leu.2404350","volume":"20","author":"T Krejsgaard","year":"2006","unstructured":"Krejsgaard T, Vetter-Kauczok CS, Woetmann A, Lovato P, Labuda T, Eriksen KW, et al. Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia. 2006;20:1759\u201366.","journal-title":"Leukemia"},{"key":"2692_CR141","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1093\/carcin\/bgz121","volume":"41","author":"H Hu","year":"2020","unstructured":"Hu H, Zhang Q, Chen W, Wu T, Liu S, Li X, et al. MicroRNA-301a promotes pancreatic cancer invasion and metastasis through the JAK\/STAT3 signaling pathway by targeting SOCS5. Carcinogenesis. 2020;41:502\u201314.","journal-title":"Carcinogenesis"},{"key":"2692_CR142","doi-asserted-by":"publisher","first-page":"e12882","DOI":"10.1111\/jfbc.12882","volume":"43","author":"JT Lin","year":"2019","unstructured":"Lin JT, Chang YY, Chen YC, Liao PL, Yang DJ. Litchi (Litchi chinensis Sonn.) flower proanthocyanidin fraction exhibited protective efficacy to suppress nickel-induced expression for vascular endothelial growth factor in HepG2 cells. J Food Biochem. 2019;43:e12882.","journal-title":"J Food Biochem"},{"key":"2692_CR143","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s12079-020-00548-5","volume":"14","author":"S Masoumi-Dehghi","year":"2020","unstructured":"Masoumi-Dehghi S, Babashah S, Sadeghizadeh M. microRNA-141-3p-containing small extracellular vesicles derived from epithelial ovarian cancer cells promote endothelial cell angiogenesis through activating the JAK\/STAT3 and NF-\u03baB signaling pathways. J cell communication Signal. 2020;14:233\u201344.","journal-title":"J cell communication Signal"},{"key":"2692_CR144","doi-asserted-by":"publisher","first-page":"15440","DOI":"10.1038\/ncomms15440","volume":"8","author":"A Sucker","year":"2017","unstructured":"Sucker A, Zhao F, Pieper N, Heeke C, Maltaner R, Stadtler N, et al. Acquired IFN\u03b3 resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions. Nat Commun. 2017;8:15440.","journal-title":"Nat Commun"},{"key":"2692_CR145","doi-asserted-by":"publisher","first-page":"1297932","DOI":"10.3389\/fimmu.2023.1297932","volume":"14","author":"JB Iorgulescu","year":"2023","unstructured":"Iorgulescu JB, Ruthen N, Ahn R, Panagioti E, Gokhale PC, Neagu M, et al. Antigen presentation deficiency, mesenchymal differentiation, and resistance to immunotherapy in the murine syngeneic CT2A tumor model. Front Immunol. 2023;14:1297932.","journal-title":"Front Immunol"},{"key":"2692_CR146","doi-asserted-by":"publisher","first-page":"e0146325","DOI":"10.1371\/journal.pone.0146325","volume":"11","author":"R Heise","year":"2016","unstructured":"Heise R, Amann PM, Ensslen S, Marquardt Y, Czaja K, Joussen S, et al. Interferon Alpha Signalling and Its Relevance for the Upregulatory Effect of Transporter Proteins Associated with Antigen Processing (TAP) in Patients with Malignant Melanoma. PLoS ONE. 2016;11:e0146325.","journal-title":"PLoS ONE"},{"key":"2692_CR147","doi-asserted-by":"publisher","first-page":"120418","DOI":"10.1016\/j.cca.2025.120418","volume":"576","author":"G Gupta","year":"2025","unstructured":"Gupta G, Afzal M, Goyal A, PadmaPriya G, Srivastava M, Chennakesavulu K, et al. Beta-2 microglobulin in lymphoma. Clin Chim Acta. 2025;576:120418.","journal-title":"Clin Chim Acta"},{"key":"2692_CR148","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1099\/vir.0.054486-0","volume":"94","author":"F Zhou","year":"2013","unstructured":"Zhou F, Chen J, Zhao KN. Human papillomavirus 16-encoded E7 protein inhibits IFN-\u03b3-mediated MHC class I antigen presentation and CTL-induced lysis by blocking IRF-1 expression in mouse keratinocytes. J Gen Virol. 2013;94:2504\u201314.","journal-title":"J Gen Virol"},{"key":"2692_CR149","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.canlet.2008.02.055","volume":"267","author":"B Quesnel","year":"2008","unstructured":"Quesnel B. Dormant tumor cells as a therapeutic target? Cancer Lett. 2008;267:10\u20137.","journal-title":"Cancer Lett"},{"key":"2692_CR150","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13045-017-0474-3","volume":"10","author":"CY Ok","year":"2017","unstructured":"Ok CY, Young KH. Checkpoint inhibitors in hematological malignancies. J Hematol Oncol. 2017;10:103.","journal-title":"J Hematol Oncol"},{"key":"2692_CR151","doi-asserted-by":"publisher","first-page":"1365894","DOI":"10.3389\/fimmu.2024.1365894","volume":"15","author":"AA Ibrahim","year":"2024","unstructured":"Ibrahim AA, Fujimura T, Uno T, Terada T, Hirano KI, Hosokawa H, et al. Plasminogen activator inhibitor-1 promotes immune evasion in tumors by facilitating the expression of programmed cell death-ligand 1. Front Immunol. 2024;15:1365894.","journal-title":"Front Immunol"},{"key":"2692_CR152","doi-asserted-by":"publisher","first-page":"16998","DOI":"10.1038\/s41598-023-42948-8","volume":"13","author":"R Wu","year":"2023","unstructured":"Wu R, Liu W, Yang Q, Zhang J, Hou P, Xiong J, et al. LncTUG1 promotes hepatocellular carcinoma immune evasion via upregulating PD-L1 expression. Sci Rep. 2023;13:16998.","journal-title":"Sci Rep"},{"key":"2692_CR153","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41417-025-00890-z","volume":"32","author":"Z Xie","year":"2025","unstructured":"Xie Z, Wu Y, Peng N, Wang J, Wang H, Zhao L. BAIAP2L2 facilitates hepatocellular carcinoma progression and immune evasion of via targeting JAK1-mediated pathway and PD-L1 expression. Cancer Gene Ther. 2025;32:464\u201374.","journal-title":"Cancer Gene Ther"},{"key":"2692_CR154","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/cac2.12619","volume":"44","author":"F He","year":"2024","unstructured":"He F, Gong Y, Tao G, Zhang J, Wu Q, Tan Y, et al. Targeting the LMP1-ALIX axis in EBV(+) nasopharyngeal carcinoma inhibits immunosuppressive small extracellular vesicle secretion and boosts anti-tumor immunity. Cancer Commun (London England). 2024;44:1391\u2013413.","journal-title":"Cancer Commun (London England)"},{"key":"2692_CR155","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1038\/s41388-024-03140-y","volume":"43","author":"H Han","year":"2024","unstructured":"Han H, Shi Q, Zhang Y, Ding M, He X, Liu C, et al. RBM12 drives PD-L1-mediated immune evasion in hepatocellular carcinoma by increasing JAK1 mRNA translation. Oncogene. 2024;43:3062\u201377.","journal-title":"Oncogene"},{"key":"2692_CR156","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41586-025-09000-3","volume":"643","author":"J Zhou","year":"2025","unstructured":"Zhou J, Tison K, Zhou H, Bai L, Acharyya RK, McEachern D, et al. STAT5 and STAT3 balance shapes dendritic cell function and tumour immunity. Nature. 2025;643:519\u201328.","journal-title":"Nature"},{"key":"2692_CR157","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1136\/gutjnl-2020-322924","volume":"71","author":"TX Huang","year":"2022","unstructured":"Huang TX, Tan XY, Huang HS, Li YT, Liu BL, Liu KS, et al. Targeting cancer-associated fibroblast-secreted WNT2 restores dendritic cell-mediated antitumour immunity. Gut. 2022;71:333\u201344.","journal-title":"Gut"},{"key":"2692_CR158","doi-asserted-by":"publisher","first-page":"112734","DOI":"10.1016\/j.yexcr.2021.112734","volume":"406","author":"S Yu","year":"2021","unstructured":"Yu S, Li Q, Wang Y, Cui Y, Yu Y, Li W, et al. Tumor-derived LIF promotes chemoresistance via activating tumor-associated macrophages in gastric cancers. Exp Cell Res. 2021;406:112734.","journal-title":"Exp Cell Res"},{"key":"2692_CR159","doi-asserted-by":"publisher","first-page":"e70340","DOI":"10.1002\/ctm2.70340","volume":"15","author":"J Liu","year":"2025","unstructured":"Liu J, Zhang W, Chen L, Wang X, Mao X, Wu Z, et al. VSIG4 Promotes Tumour-Associated Macrophage M2 Polarization and Immune Escape in Colorectal Cancer via Fatty Acid Oxidation Pathway. Clin Transl Med. 2025;15:e70340.","journal-title":"Clin Transl Med"},{"key":"2692_CR160","doi-asserted-by":"crossref","unstructured":"Huang H, Pan Y, Mai Q, Zhang C, Du Q, Liao Y, et al. Targeting CDCP1 boost CD8\u2009+\u2009T cells-mediated cytotoxicity in cervical cancer via the JAK\/STAT signaling pathway. J Immunother Cancer. 2024;12:e009416.","DOI":"10.1136\/jitc-2024-009416"},{"key":"2692_CR161","first-page":"186","volume":"21","author":"J Shao","year":"2024","unstructured":"Shao J, Deng G, Wen G, Xie X. JAK\/STAT Signaling Pathway Mediates Anti-Tumor Immunity of CD8\u2009+\u2009T Cells in Renal Cancer. Iran J Immunol. 2024;21:186\u2013200.","journal-title":"Iran J Immunol"},{"key":"2692_CR162","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.bcp.2017.08.019","volume":"145","author":"W He","year":"2017","unstructured":"He W, Zhu Y, Mu R, Xu J, Zhang X, Wang C, et al. A Jak2-selective inhibitor potently reverses the immune suppression by modulating the tumor microenvironment for cancer immunotherapy. Biochem Pharmacol. 2017;145:132\u201346.","journal-title":"Biochem Pharmacol"},{"key":"2692_CR163","doi-asserted-by":"publisher","first-page":"2581910","DOI":"10.1080\/2162402X.2025.2581910","volume":"14","author":"X Han","year":"2025","unstructured":"Han X, Bai X, Wang N, Sun Y, Hu J, Li L, et al. Inhibiting SLAMF8 modulates tumor-associated macrophages and restores CD8\u2009+\u2009T cell-mediated antitumor immunity in colorectal cancer. Oncoimmunology. 2025;14:2581910.","journal-title":"Oncoimmunology"},{"key":"2692_CR164","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cytogfr.2025.01.003","volume":"85","author":"WL Thuya","year":"2025","unstructured":"Thuya WL, Cao Y, Ho PC, Wong AL, Wang L, Zhou J, et al. Insights into IL-6\/JAK\/STAT3 signaling in the tumor microenvironment: Implications for cancer therapy. Cytokine Growth Factor Rev. 2025;85:26\u201342.","journal-title":"Cytokine Growth Factor Rev"},{"key":"2692_CR165","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12943-025-02312-y","volume":"24","author":"H Umeda","year":"2025","unstructured":"Umeda H, Shigeyasu K, Takahashi T, Moriwake K, Kondo Y, Yoshida K, et al. ADAR1-high tumor-associated macrophages induce drug resistance and are therapeutic targets in colorectal cancer. Mol Cancer. 2025;24:116.","journal-title":"Mol Cancer"},{"key":"2692_CR166","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/s40001-023-01246-9","volume":"28","author":"L Gu","year":"2023","unstructured":"Gu L, Feng C, Li M, Hong Z, Di W, Qiu L. Exosomal NOX1 promotes tumor-associated macrophage M2 polarization-mediated cancer progression by stimulating ROS production in cervical cancer: a preliminary study. Eur J Med Res. 2023;28:323.","journal-title":"Eur J Med Res"},{"key":"2692_CR167","doi-asserted-by":"publisher","first-page":"e3446","DOI":"10.1002\/jgm.3446","volume":"24","author":"S Yang","year":"2022","unstructured":"Yang S, Zhao H, Xiao W, Shao L, Zhao C, Sun P. Extracellular vesicle-packaged miR-181c-5p from epithelial ovarian cancer cells promotes M2 polarization of tumor-associated macrophages via the KAT2B\/HOXA10 axis. J Gene Med. 2022;24:e3446.","journal-title":"J Gene Med"},{"key":"2692_CR168","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1002\/art.41441","volume":"72","author":"A Najm","year":"2020","unstructured":"Najm A, Masson FM, Preuss P, Georges S, Ory B, Quillard T, et al. MicroRNA-17-5p Reduces Inflammation and Bone Erosions in Mice With Collagen-Induced Arthritis and Directly Targets the JAK\/STAT Pathway in Rheumatoid Arthritis Fibroblast-like Synoviocytes. Arthritis Rheumatol. 2020;72:2030\u20139.","journal-title":"Arthritis Rheumatol"},{"key":"2692_CR169","doi-asserted-by":"publisher","first-page":"56634","DOI":"10.1021\/acsami.4c10036","volume":"16","author":"Y Li","year":"2024","unstructured":"Li Y, Li M, Zheng J, Ma Z, Yu T, Zhu Y, et al. Ultrasound-Responsive Nanocarriers Delivering siRNA and Fe(3)O(4) Nanoparticles Reprogram Macrophages and Inhibit M2 Polarization for Enhanced NSCLC Immunotherapy. ACS Appl Mater Interfaces. 2024;16:56634\u201352.","journal-title":"ACS Appl Mater Interfaces"},{"key":"2692_CR170","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41392-025-02559-3","volume":"11","author":"B Singh","year":"2026","unstructured":"Singh B, Gaur P, Bose P, Zhang Y, Li Y, Zhang Z, et al. Extracellular vesicle-derived miRNA-182-5p educates macrophages towards an immunosuppressive phenotype in pancreatic cancer. Signal Transduct Target Ther. 2026;11:31.","journal-title":"Signal Transduct Target Ther"},{"key":"2692_CR171","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s12935-024-03453-8","volume":"24","author":"P Su","year":"2024","unstructured":"Su P, Yu T, Zhang Y, Huang H, Chen M, Cao C, et al. Upregulation of MELK promotes chemoresistance and induces macrophage M2 polarization via CSF-1\/JAK2\/STAT3 pathway in gastric cancer. Cancer Cell Int. 2024;24:287.","journal-title":"Cancer Cell Int"},{"key":"2692_CR172","doi-asserted-by":"publisher","first-page":"104861","DOI":"10.1016\/j.critrevonc.2025.104861","volume":"214","author":"Y Yao","year":"2025","unstructured":"Yao Y, Tao G, Xie D, Xu Y, Li L. Effect of JAK\/STAT signaling on anti-PD-L1 immunotherapy efficacy in lung cancer. Crit Rev Oncol Hematol. 2025;214:104861.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2692_CR173","doi-asserted-by":"publisher","first-page":"2525444","DOI":"10.1080\/02656736.2025.2525444","volume":"42","author":"J Li","year":"2025","unstructured":"Li J, Zhao X, Qi M, Chen X, Chen W, Zhang S, et al. Cryoablation combined with programmed cell death protein 1 (PD-1) inhibitors regulates myeloid-derived suppressor cells (MDSCs) through the JAK2-STAT3-S100A8\/A9 axis in mice with Lewis lung carcinoma. Int J Hyperth. 2025;42:2525444.","journal-title":"Int J Hyperth"},{"key":"2692_CR174","doi-asserted-by":"publisher","first-page":"5224","DOI":"10.1038\/s41388-021-01906-2","volume":"40","author":"S Hamalian","year":"2021","unstructured":"Hamalian S, G\u00fcth R, Runa F, Sanchez F, Vickers E, Agajanian M, et al. A SNAI2-PEAK1-INHBA stromal axis drives progression and lapatinib resistance in HER2-positive breast cancer by supporting subpopulations of tumor cells positive for antiapoptotic and stress signaling markers. Oncogene. 2021;40:5224\u201335.","journal-title":"Oncogene"},{"key":"2692_CR175","doi-asserted-by":"crossref","unstructured":"Deng D, Patel R, Chiang CY, Hou P. Role of the Tumor Microenvironment in Regulating Pancreatic Cancer Therapy Resistance. Cells. 2022;11:2952.","DOI":"10.3390\/cells11192952"},{"key":"2692_CR176","doi-asserted-by":"crossref","unstructured":"Romano V, Belviso I, Venuta A, Ruocco MR, Masone S, Aliotta F, et al. Influence of Tumor Microenvironment and Fibroblast Population Plasticity on Melanoma Growth, Therapy Resistance and Immunoescape. Int J Mol Sci. 2021;22:5283.","DOI":"10.3390\/ijms22105283"},{"key":"2692_CR177","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/ijc.32123","volume":"145","author":"S Dolatabadi","year":"2019","unstructured":"Dolatabadi S, Jonasson E, Lind\u00e9n M, Fereydouni B, B\u00e4cksten K, Nilsson M, et al. JAK-STAT signalling controls cancer stem cell properties including chemotherapy resistance in myxoid liposarcoma. Int J Cancer. 2019;145:435\u201349.","journal-title":"Int J Cancer"},{"key":"2692_CR178","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1186\/s13046-019-1405-7","volume":"38","author":"SY Park","year":"2019","unstructured":"Park SY, Lee CJ, Choi JH, Kim JH, Kim JW, Kim JY, et al. The JAK2\/STAT3\/CCND2 Axis promotes colorectal Cancer stem cell persistence and radioresistance. J Exp Clin Cancer Res. 2019;38:399.","journal-title":"J Exp Clin Cancer Res"},{"key":"2692_CR179","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12935-025-03681-6","volume":"25","author":"Y Dai","year":"2025","unstructured":"Dai Y, Cui C, Jiao D, Zhu X. JAK\/STAT signaling as a key regulator of ferroptosis: mechanisms and therapeutic potentials in cancer and diseases. Cancer Cell Int. 2025;25:83.","journal-title":"Cancer Cell Int"},{"key":"2692_CR180","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13045-021-01223-x","volume":"15","author":"H Li","year":"2022","unstructured":"Li H, Yang P, Wang J, Zhang J, Ma Q, Jiang Y, et al. HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk. J Hematol Oncol. 2022;15:2.","journal-title":"J Hematol Oncol"},{"key":"2692_CR181","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.ctrv.2012.04.007","volume":"38","author":"Y Guo","year":"2012","unstructured":"Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev. 2012;38:904\u201310.","journal-title":"Cancer Treat Rev"},{"key":"2692_CR182","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1097\/JTO.0000000000000193","volume":"9","author":"L Song","year":"2014","unstructured":"Song L, Smith MA, Doshi P, Sasser K, Fulp W, Altiok S, et al. Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer. J Thorac Oncol. 2014;9:974\u201382.","journal-title":"J Thorac Oncol"},{"key":"2692_CR183","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1182\/bloodadvances.2020004016","volume":"5","author":"SK Pierson","year":"2021","unstructured":"Pierson SK, Shenoy S, Oromendia AB, Gorzewski AM, Langan Pai RA, Nabel CS, et al. Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease. Blood Adv. 2021;5:3445\u201356.","journal-title":"Blood Adv"},{"key":"2692_CR184","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1158\/1535-7163.MCT-10-0502","volume":"10","author":"L Song","year":"2011","unstructured":"Song L, Rawal B, Nemeth JA, Haura EB. JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Mol Cancer Ther. 2011;10:481\u201394.","journal-title":"Mol Cancer Ther"},{"key":"2692_CR185","doi-asserted-by":"publisher","first-page":"114275","DOI":"10.5306\/wjco.v16.i12.114275","volume":"16","author":"G Calibasi-Kocal","year":"2025","unstructured":"Calibasi-Kocal G. Inflammatory cytokine-associated cisplatin resistance in non-small cell lung cancer and re-sensitization through interleukin-6 receptor blockade. World J Clin Oncol. 2025;16:114275.","journal-title":"World J Clin Oncol"},{"key":"2692_CR186","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1200\/JCO.23.01965","volume":"43","author":"IM Chen","year":"2025","unstructured":"Chen IM, Johansen JS, Theile S, Silverman LM, Pelz KR, Madsen K, et al. Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia. J Clin Oncol. 2025;43:2107\u201318.","journal-title":"J Clin Oncol"},{"key":"2692_CR187","doi-asserted-by":"crossref","unstructured":"Holmstroem RB, Nielsen OH, Jacobsen S, Riis LB, Theile S, Bjerrum JT, et al. COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis. J Immunother Cancer. 2022;10:e005111.","DOI":"10.1136\/jitc-2022-005111"},{"key":"2692_CR188","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13046-023-02711-3","volume":"42","author":"Y Cui","year":"2023","unstructured":"Cui Y, Li J, Zhang P, Yin D, Wang Z, Dai J, et al. B4GALT1 promotes immune escape by regulating the expression of PD-L1 at multiple levels in lung adenocarcinoma. J Exp Clin Cancer Res. 2023;42:146.","journal-title":"J Exp Clin Cancer Res"},{"key":"2692_CR189","doi-asserted-by":"publisher","first-page":"e1441","DOI":"10.1002\/cti2.1441","volume":"12","author":"Y Cao","year":"2023","unstructured":"Cao Y, Wang J, Jiang S, Lyu M, Zhao F, Liu J, et al. JAK1\/2 inhibitor ruxolitinib promotes the expansion and suppressive action of polymorphonuclear myeloid-derived suppressor cells via the JAK\/STAT and ROS-MAPK\/NF-\u03baB signalling pathways in acute graft-versus-host disease. Clin Transl Immunol. 2023;12:e1441.","journal-title":"Clin Transl Immunol"},{"key":"2692_CR190","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1172\/JCI126022","volume":"129","author":"LC Chan","year":"2019","unstructured":"Chan LC, Li CW, Xia W, Hsu JM, Lee HH, Cha JH, et al. IL-6\/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J Clin Invest. 2019;129:3324\u201338.","journal-title":"J Clin Invest"},{"key":"2692_CR191","doi-asserted-by":"publisher","first-page":"e2506485123","DOI":"10.1073\/pnas.2506485123","volume":"123","author":"M Kojima","year":"2026","unstructured":"Kojima M, Izawa K, Ando T, Maeda K, Kaitani A, Nakano N, et al. Constitutively high levels of endogenous soluble ST2 inhibit food allergic responses in mice. Proc Natl Acad Sci U S A. 2026;123:e2506485123.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2692_CR192","doi-asserted-by":"publisher","first-page":"eady2268","DOI":"10.1126\/sciimmunol.ady2268","volume":"11","author":"K Bruton","year":"2026","unstructured":"Bruton K, Phelps A, Ariaz A, Fang A, Walker TD, Wen J, et al. Pathogenic IgE-fated memory B cell responses retain functional plasticity. Sci Immunol. 2026;11:eady2268.","journal-title":"Sci Immunol"},{"key":"2692_CR193","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ijc.28189","volume":"133","author":"A Natoli","year":"2013","unstructured":"Natoli A, L\u00fcpertz R, Merz C, M\u00fcller WW, K\u00f6hler R, Krammer PH, et al. Targeting the IL-4\/IL-13 signaling pathway sensitizes Hodgkin lymphoma cells to chemotherapeutic drugs. Int J Cancer. 2013;133:1945\u201354.","journal-title":"Int J Cancer"},{"key":"2692_CR194","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1017\/S000711451300086X","volume":"110","author":"T Sakurai","year":"2013","unstructured":"Sakurai T, Kitadate K, Nishioka H, Fujii H, Ogasawara J, Kizaki T, et al. Oligomerised lychee fruit-derived polyphenol attenuates cognitive impairment in senescence-accelerated mice and endoplasmic reticulum stress in neuronal cells. Br J Nutr. 2013;110:1549\u201358.","journal-title":"Br J Nutr"},{"key":"2692_CR195","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.bbrc.2009.03.046","volume":"382","author":"HK Lee","year":"2009","unstructured":"Lee HK, Seo IA, Shin YK, Park JW, Suh DJ, Park HT. Capsaicin inhibits the IL-6\/STAT3 pathway by depleting intracellular gp130 pools through endoplasmic reticulum stress. Biochem Biophys Res Commun. 2009;382:445\u201350.","journal-title":"Biochem Biophys Res Commun"},{"key":"2692_CR196","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1038\/onc.2015.466","volume":"35","author":"R Bharti","year":"2016","unstructured":"Bharti R, Dey G, Ojha PK, Rajput S, Jaganathan SK, Sen R, et al. Diacerein-mediated inhibition of IL-6\/IL-6R signaling induces apoptotic effects on breast cancer. Oncogene. 2016;35:3965\u201375.","journal-title":"Oncogene"},{"key":"2692_CR197","doi-asserted-by":"publisher","first-page":"205873841878163","DOI":"10.1177\/2058738418781634","volume":"32","author":"Y Huang","year":"2018","unstructured":"Huang Y, Zhang J, Wang G, Chen X, Zhang R, Liu H, et al. Oxymatrine exhibits anti-tumor activity in gastric cancer through inhibition of IL-21R-mediated JAK2\/STAT3 pathway. Int J Immunopathol Pharmacol. 2018;32:2058738418781634.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"2692_CR198","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.semcdb.2008.07.002","volume":"19","author":"W Vainchenker","year":"2008","unstructured":"Vainchenker W, Dusa A, Constantinescu SN. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol. 2008;19:385\u201393.","journal-title":"Semin Cell Dev Biol"},{"key":"2692_CR199","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799\u2013807.","journal-title":"N Engl J Med"},{"key":"2692_CR200","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372:426\u201335.","journal-title":"N Engl J Med"},{"key":"2692_CR201","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","volume":"111","author":"R Roskoski","year":"2016","unstructured":"Roskoski R. Jr. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacol Res. 2016;111:784\u2013803.","journal-title":"Pharmacol Res"},{"key":"2692_CR202","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1001\/jama.2024.20377","volume":"333","author":"D Tremblay","year":"2025","unstructured":"Tremblay D, Kremyanskaya M, Mascarenhas J, Hoffman R. Diagnosis and Treatment of Polycythemia Vera: A Review. JAMA. 2025;333:153\u201360.","journal-title":"JAMA"},{"key":"2692_CR203","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","volume":"401","author":"S Verstovsek","year":"2023","unstructured":"Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Lancet. 2023;401:269\u201380.","journal-title":"Lancet"},{"key":"2692_CR204","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/ajh.26857","volume":"98","author":"A Tefferi","year":"2023","unstructured":"Tefferi A, Primary myelofibrosis. 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:801\u201321.","journal-title":"Am J Hematol"},{"key":"2692_CR205","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/mc.23632","volume":"63","author":"A Lahera","year":"2024","unstructured":"Lahera A, Vela-Mart\u00edn L, Fern\u00e1ndez-Navarro P, Llamas P, L\u00f3pez-Lorenzo JL, Cornago J, et al. The JAK3(Q988P) mutation reveals oncogenic potential and resistance to ruxolitinib. Mol Carcinog. 2024;63:5\u201310.","journal-title":"Mol Carcinog"},{"key":"2692_CR206","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/onc.2017.339","volume":"37","author":"MR Yun","year":"2018","unstructured":"Yun MR, Choi HM, Kang HN, Lee Y, Joo HS, Kim DH, et al. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma. Oncogene. 2018;37:377\u201388.","journal-title":"Oncogene"},{"key":"2692_CR207","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s41586-018-0387-5","volume":"560","author":"JB Baell","year":"2018","unstructured":"Baell JB, Leaver DJ, Hermans SJ, Kelly GL, Brennan MS, Downer NL, et al. Inhibitors of histone acetyltransferases KAT6A\/B induce senescence and arrest tumour growth. Nature. 2018;560:253\u20137.","journal-title":"Nature"},{"key":"2692_CR208","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s11912-024-01503-y","volume":"26","author":"M Wysota","year":"2024","unstructured":"Wysota M, Konopleva M, Mitchell S. Novel Therapeutic Targets in Acute Myeloid Leukemia (AML). Curr Oncol Rep. 2024;26:409\u201320.","journal-title":"Curr Oncol Rep"},{"key":"2692_CR209","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1182\/blood.2024026388","volume":"145","author":"W Fiskus","year":"2025","unstructured":"Fiskus W, Mill CP, Bose P, Masarova L, Pemmaraju N, Dunbar A, et al. Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML. Blood. 2025;145:612\u201324.","journal-title":"Blood"},{"key":"2692_CR210","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.21873\/anticanres.15657","volume":"42","author":"JK Hong","year":"2022","unstructured":"Hong JK, Kim DY, Shin JS, Ryu YS, Moon JH, Koh DI, et al. CJ14939, a Novel JAK Inhibitor, Increases Oxaliplatin-induced Cell Death Through JAK\/STAT Pathway in Colorectal Cancer. Anticancer Res. 2022;42:1813\u20139.","journal-title":"Anticancer Res"},{"key":"2692_CR211","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1007\/s10495-014-1030-z","volume":"19","author":"Y Hu","year":"2014","unstructured":"Hu Y, Hong Y, Xu Y, Liu P, Guo DH, Chen Y. Inhibition of the JAK\/STAT pathway with ruxolitinib overcomes cisplatin resistance in non-small-cell lung cancer NSCLC. Apoptosis. 2014;19:1627\u201336.","journal-title":"Apoptosis"},{"key":"2692_CR212","doi-asserted-by":"publisher","first-page":"5658","DOI":"10.1158\/1078-0432.CCR-13-0422","volume":"19","author":"L Gu","year":"2013","unstructured":"Gu L, Liao Z, Hoang DT, Dagvadorj A, Gupta S, Blackmon S, et al. Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer. Clin Cancer Res. 2013;19:5658\u201374.","journal-title":"Clin Cancer Res"},{"key":"2692_CR213","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1158\/1535-7163.MCT-19-0508","volume":"19","author":"V Udhane","year":"2020","unstructured":"Udhane V, Maranto C, Hoang DT, Gu L, Erickson A, Devi S, et al. Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors. Mol Cancer Ther. 2020;19:231\u201346.","journal-title":"Mol Cancer Ther"},{"key":"2692_CR214","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1038\/s41401-024-01258-z","volume":"45","author":"JQ Lai","year":"2024","unstructured":"Lai JQ, Zhao LL, Hong C, Zou QM, Su JX, Li SJ, et al. Baicalein triggers ferroptosis in colorectal cancer cells via blocking the JAK2\/STAT3\/GPX4 axis. Acta Pharmacol Sin. 2024;45:1715\u201326.","journal-title":"Acta Pharmacol Sin"},{"key":"2692_CR215","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.canlet.2014.11.049","volume":"357","author":"J Chun","year":"2015","unstructured":"Chun J, Li RJ, Cheng MS, Kim YS. Alantolactone selectively suppresses STAT3 activation and exhibits potent anticancer activity in MDA-MB-231 cells. Cancer Lett. 2015;357:393\u2013403.","journal-title":"Cancer Lett"},{"key":"2692_CR216","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1158\/2326-6066.CIR-15-0235","volume":"4","author":"S Yang","year":"2016","unstructured":"Yang S, Imamura Y, Jenkins RW, Ca\u00f1adas I, Kitajima S, Aref A, et al. Autophagy Inhibition Dysregulates TBK1 Signaling and Promotes Pancreatic Inflammation. Cancer Immunol Res. 2016;4:520\u201330.","journal-title":"Cancer Immunol Res"},{"key":"2692_CR217","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1007\/s00277-024-05867-w","volume":"103","author":"S Isfort","year":"2024","unstructured":"Isfort S, von Bubnoff N, Al-Ali HK, Becker H, G\u00f6tze T, le Coutre P, et al. FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN). Ann Hematol. 2024;103:2775\u201385.","journal-title":"Ann Hematol"},{"key":"2692_CR218","first-page":"eade8520","volume-title":"JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma","author":"J Zak","year":"2024","unstructured":"Zak J, Pratumchai I, Marro BS, Marquardt KL, Zavareh RB, Lairson LL, et al. JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma. Volume 384. New York, N.Y.: Science; 2024. p. eade8520."},{"key":"2692_CR219","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1182\/blood.2020004823","volume":"135","author":"M Jagasia","year":"2020","unstructured":"Jagasia M, Perales MA, Schroeder MA, Ali H, Shah NN, Chen YB, et al. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2020;135:1739\u201349.","journal-title":"Blood"},{"key":"2692_CR220","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2033122","volume":"385","author":"R Zeiser","year":"2021","unstructured":"Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, et al. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. N Engl J Med. 2021;385:228\u201338.","journal-title":"N Engl J Med"},{"key":"2692_CR221","first-page":"e14","volume":"9","author":"R Zeiser","year":"2022","unstructured":"Zeiser R, Soci\u00e9 G, Schroeder MA, Abhyankar S, Vaz CP, Kwon M, et al. Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial. The Lancet. Haematology. 2022;9:e14\u201325.","journal-title":"Haematology"},{"key":"2692_CR222","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1517\/13543784.2011.601739","volume":"20","author":"AK Mankan","year":"2011","unstructured":"Mankan AK, Greten FR. Inhibiting signal transducer and activator of transcription 3: rationality and rationale design of inhibitors. Expert Opin Investig Drugs. 2011;20:1263\u201375.","journal-title":"Expert Opin Investig Drugs"},{"key":"2692_CR223","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1517\/13543776.2011.539205","volume":"21","author":"BD Page","year":"2011","unstructured":"Page BD, Ball DP, Gunning PT. Signal transducer and activator of transcription 3 inhibitors: a patent review. Expert Opin Ther Pat. 2011;21:65\u201383.","journal-title":"Expert Opin Ther Pat"},{"key":"2692_CR224","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s00280-016-3181-9","volume":"78","author":"BF Kiesel","year":"2016","unstructured":"Kiesel BF, Parise RA, Guo J, Huryn DM, Johnston PA, Colombo R, et al. Toxicity, pharmacokinetics and metabolism of a novel inhibitor of IL-6-induced STAT3 activation. Cancer Chemother Pharmacol. 2016;78:1225\u201335.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2692_CR225","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1158\/1078-0432.CCR-24-2920","volume":"31","author":"AM Tsimberidou","year":"2025","unstructured":"Tsimberidou AM, Vining DJ, Arora SP, de Achaval S, Larson J, Kauh J, et al. Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2025;31:965\u201374.","journal-title":"Clin Cancer Res"},{"key":"2692_CR226","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1089\/jmf.2023.K.0026","volume":"26","author":"HK Choi","year":"2023","unstructured":"Choi HK, Park SH, Lee J, Hwang JT. Review of Patents for Anticancer Agents Targeting Adenosine Monophosphate-Activated Protein Kinase. J Med Food. 2023;26:605\u201315.","journal-title":"J Med Food"},{"key":"2692_CR227","doi-asserted-by":"publisher","first-page":"713859","DOI":"10.1155\/2013\/713859","volume":"2013","author":"Q Tang","year":"2013","unstructured":"Tang Q, Li J, Zhu H, Li P, Zou Z, Xiao Y. Hmgb1-IL-23-IL-17-IL-6-Stat3 axis promotes tumor growth in murine models of melanoma. Mediat Inflamm. 2013;2013:713859.","journal-title":"Mediat Inflamm"},{"key":"2692_CR228","doi-asserted-by":"publisher","first-page":"869","DOI":"10.7150\/ijbs.56152","volume":"17","author":"Q Zhao","year":"2021","unstructured":"Zhao Q, Cheng X, Guo J, Bi Y, Kuang L, Ren J, et al. MLKL inhibits intestinal tumorigenesis by suppressing STAT3 signaling pathway. Int J Biol Sci. 2021;17:869\u201381.","journal-title":"Int J Biol Sci"},{"key":"2692_CR229","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1111\/j.1349-7006.2012.02363.x","volume":"103","author":"D Harada","year":"2012","unstructured":"Harada D, Takigawa N, Ochi N, Ninomiya T, Yasugi M, Kubo T, et al. JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation. Cancer Sci. 2012;103:1795\u2013802.","journal-title":"Cancer Sci"},{"key":"2692_CR230","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1124\/jpet.109.162669","volume":"333","author":"S Jaganathan","year":"2010","unstructured":"Jaganathan S, Yue P, Turkson J. Enhanced sensitivity of pancreatic cancer cells to concurrent inhibition of aberrant signal transducer and activator of transcription 3 and epidermal growth factor receptor or Src. J Pharmacol Exp Ther. 2010;333:373\u201381.","journal-title":"J Pharmacol Exp Ther"},{"key":"2692_CR231","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/mc.22951","volume":"58","author":"H Zheng","year":"2019","unstructured":"Zheng H, Yang L, Kang Y, Chen M, Lin S, Xiang Y, et al. Alantolactone sensitizes human pancreatic cancer cells to EGFR inhibitors through the inhibition of STAT3 signaling. Mol Carcinog. 2019;58:565\u201376.","journal-title":"Mol Carcinog"},{"key":"2692_CR232","doi-asserted-by":"publisher","first-page":"107101","DOI":"10.1016\/j.bioorg.2024.107101","volume":"143","author":"HA Elsebaie","year":"2024","unstructured":"Elsebaie HA, El-Moselhy TF, El-Bastawissy EA, Elberembally KM, Badi RM, Elkaeed EB, et al. Development of new thieno[2,3-d]pyrimidines as dual EGFR and STAT3 inhibitors endowed with anticancer and pro-apoptotic activities. Bioorg Chem. 2024;143:107101.","journal-title":"Bioorg Chem"},{"key":"2692_CR233","doi-asserted-by":"publisher","first-page":"107969","DOI":"10.1016\/j.pharmthera.2021.107969","volume":"230","author":"L Zhang","year":"2022","unstructured":"Zhang L, Kuca K, You L, Zhao Y, Musilek K, Nepovimova E, et al. Signal transducer and activator of transcription 3 signaling in tumor immune evasion. Pharmacol Ther. 2022;230:107969.","journal-title":"Pharmacol Ther"},{"key":"2692_CR234","doi-asserted-by":"publisher","first-page":"767939","DOI":"10.3389\/fimmu.2021.767939","volume":"12","author":"A Allam","year":"2021","unstructured":"Allam A, Yakou M, Pang L, Ernst M, Huynh J. Exploiting the STAT3 Nexus in Cancer-Associated Fibroblasts to Improve Cancer Therapy. Front Immunol. 2021;12:767939.","journal-title":"Front Immunol"},{"key":"2692_CR235","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.ijrobp.2017.11.043","volume":"100","author":"OM Rahal","year":"2018","unstructured":"Rahal OM, Wolfe AR, Mandal PK, Larson R, Tin S, Jimenez C, et al. Blocking Interleukin (IL)4- and IL13-Mediated Phosphorylation of STAT6 (Tyr641) Decreases M2 Polarization of Macrophages and Protects Against Macrophage-Mediated Radioresistance of Inflammatory Breast Cancer. Int J Radiat Oncol Biol Phys. 2018;100:1034\u201343.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2692_CR236","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s40425-018-0436-5","volume":"6","author":"MJ Reilley","year":"2018","unstructured":"Reilley MJ, McCoon P, Cook C, Lyne P, Kurzrock R, Kim Y, et al. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. J Immunother Cancer. 2018;6:119.","journal-title":"J Immunother Cancer"},{"key":"2692_CR237","doi-asserted-by":"publisher","first-page":"eadp7022","DOI":"10.1126\/sciadv.adp7022","volume":"10","author":"Z Wang","year":"2024","unstructured":"Wang Z, Chen Y, Fang H, Xiao K, Wu Z, Xie X, et al. Reprogramming cellular senescence in the tumor microenvironment augments cancer immunotherapy through multifunctional nanocrystals. Sci Adv. 2024;10:eadp7022.","journal-title":"Sci Adv"},{"key":"2692_CR238","doi-asserted-by":"publisher","first-page":"155408","DOI":"10.1016\/j.prp.2024.155408","volume":"260","author":"WH Almalki","year":"2024","unstructured":"Almalki WH, Almujri SS. Circular RNAs and the JAK\/STAT pathway: New frontiers in cancer therapeutics. Pathol Res Pract. 2024;260:155408.","journal-title":"Pathol Res Pract"},{"key":"2692_CR239","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","volume":"8","author":"C Xue","year":"2023","unstructured":"Xue C, Yao Q, Gu X, Shi Q, Yuan X, Chu Q, et al. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduct Target Ther. 2023;8:204.","journal-title":"Signal Transduct Target Ther"},{"key":"2692_CR240","doi-asserted-by":"publisher","first-page":"20059","DOI":"10.1074\/jbc.R700016200","volume":"282","author":"C Schindler","year":"2007","unstructured":"Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem. 2007;282:20059\u201363.","journal-title":"J Biol Chem"},{"key":"2692_CR241","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1002\/j.1460-2075.1995.tb07128.x","volume":"14","author":"D Guschin","year":"1995","unstructured":"Guschin D, Rogers N, Briscoe J, Witthuhn B, Watling D, Horn F, et al. A major role for the protein tyrosine kinase JAK1 in the JAK\/STAT signal transduction pathway in response to interleukin-6. Embo j. 1995;14:1421\u20139.","journal-title":"Embo j"},{"key":"2692_CR242","first-page":"232","volume":"69","author":"WS Modi","year":"1995","unstructured":"Modi WS, Farrar WL, Howard OM. Confirmed assignment of a novel human tyrosine kinase gene (JAK1A) to 1p32.3\u2013>p31.3 by nonisotopic in situ hybridization. Cytogenet Cell Genet. 1995;69:232\u20134.","journal-title":"Cytogenet Cell Genet"},{"key":"2692_CR243","doi-asserted-by":"publisher","first-page":"e0139663","DOI":"10.1371\/journal.pone.0139663","volume":"10","author":"H Dai","year":"2015","unstructured":"Dai H, Ehrentraut S, Nagel S, Eberth S, Pommerenke C, Dirks WG, et al. Genomic Landscape of Primary Mediastinal B-Cell Lymphoma Cell Lines. PLoS ONE. 2015;10:e0139663.","journal-title":"PLoS ONE"},{"key":"2692_CR244","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1006\/geno.1996.0520","volume":"37","author":"MC Riedy","year":"1996","unstructured":"Riedy MC, Dutra AS, Blake TB, Modi W, Lal BK, Davis J, et al. Genomic sequence, organization, and chromosomal localization of human JAK3. Genomics. 1996;37:57\u201361.","journal-title":"Genomics"},{"key":"2692_CR245","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1586\/era.10.203","volume":"11","author":"FM Uckun","year":"2011","unstructured":"Uckun FM, Pitt J, Qazi S. JAK3 pathway is constitutively active in B-lineage acute lymphoblastic leukemia. Expert Rev Anticancer Ther. 2011;11:37\u201348.","journal-title":"Expert Rev Anticancer Ther"},{"key":"2692_CR246","doi-asserted-by":"crossref","unstructured":"Lou N, Yang M, Xie Z, Gao R, Zhang L, Tang L, et al. JAK3 (A573V) and JAK3 (M511I) mutations in peripheral T-cell lymphoma mediating resistance to anti-PD-1 therapy through the STAT3\/PD-L1 pathway. J Immunother Cancer. 2025;13:e010783.","DOI":"10.1136\/jitc-2024-010783"},{"key":"2692_CR247","first-page":"277","volume":"5","author":"JJ Krolewski","year":"1990","unstructured":"Krolewski JJ, Lee R, Eddy R, Shows TB, Dalla-Favera R. Identification and chromosomal mapping of new human tyrosine kinase genes. Oncogene. 1990;5:277\u201382.","journal-title":"Oncogene"},{"key":"2692_CR248","first-page":"207","volume":"77","author":"K Yamamoto","year":"1997","unstructured":"Yamamoto K, Kobayashi H, Arai A, Miura O, Hirosawa S, Miyasaka N. cDNA cloning, expression and chromosome mapping of the human STAT4 gene: both STAT4 and STAT1 genes are mapped to 2q32.2\u2013>q32.3. Cytogenet Cell Genet. 1997;77:207\u201310.","journal-title":"Cytogenet Cell Genet"},{"key":"2692_CR249","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1126\/science.8197455","volume":"264","author":"JE Darnell Jr","year":"1994","unstructured":"Darnell JE Jr., Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264:1415\u201321.","journal-title":"Science"},{"key":"2692_CR250","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1093\/nar\/23.3.459","volume":"23","author":"R Yan","year":"1995","unstructured":"Yan R, Qureshi S, Zhong Z, Wen Z, Darnell JE Jr. The genomic structure of the STAT genes: multiple exons in coincident sites in Stat1 and Stat2. Nucleic Acids Res. 1995;23:459\u201363.","journal-title":"Nucleic Acids Res"},{"key":"2692_CR251","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1038\/s12276-020-00506-6","volume":"52","author":"CJ Lee","year":"2020","unstructured":"Lee CJ, An HJ, Cho ES, Kang HC, Lee JY, Lee HS, et al. Stat2 stability regulation: an intersection between immunity and carcinogenesis. Exp Mol Med. 2020;52:1526\u201336.","journal-title":"Exp Mol Med"},{"key":"2692_CR252","first-page":"e25790","volume":"2","author":"HC Steen","year":"2013","unstructured":"Steen HC, Gamero AM. STAT2 phosphorylation and signaling. Jakstat. 2013;2:e25790.","journal-title":"Jakstat"},{"key":"2692_CR253","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1080\/08830185.2024.2395274","volume":"43","author":"M Tolomeo","year":"2024","unstructured":"Tolomeo M, Cascio A. STAT4 and STAT6, their role in cellular and humoral immunity and in diverse human diseases. Int Rev Immunol. 2024;43:394\u2013418.","journal-title":"Int Rev Immunol"},{"key":"2692_CR254","doi-asserted-by":"publisher","first-page":"e2306761120","DOI":"10.1073\/pnas.2306761120","volume":"120","author":"G Scarno","year":"2023","unstructured":"Scarno G, Mazej J, Laffranchi M, Di Censo C, Mattiola I, Candelotti AM, et al. Divergent roles for STAT4 in shaping differentiation of cytotoxic ILC1 and NK cells during gut inflammation. Proc Natl Acad Sci U S A. 2023;120:e2306761120.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2692_CR255","doi-asserted-by":"crossref","unstructured":"Suske T, Sorger H, Manhart G, Ruge F, Prutsch N, Zimmerman MW, et al. Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia. J Clin Invest. 2024;134:e168536.","DOI":"10.1172\/JCI168536"},{"key":"2692_CR256","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1086\/302599","volume":"65","author":"HW Davey","year":"1999","unstructured":"Davey HW, Wilkins RJ, Waxman DJ. STAT5 signaling in sexually dimorphic gene expression and growth patterns. Am J Hum Genet. 1999;65:959\u201365.","journal-title":"Am J Hum Genet"},{"key":"2692_CR257","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.coi.2012.01.015","volume":"24","author":"LM Heltemes-Harris","year":"2012","unstructured":"Heltemes-Harris LM, Farrar MA. The role of STAT5 in lymphocyte development and transformation. Curr Opin Immunol. 2012;24:146\u201352.","journal-title":"Curr Opin Immunol"},{"key":"2692_CR258","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1006\/geno.1998.5436","volume":"52","author":"BK Patel","year":"1998","unstructured":"Patel BK, Keck CL, O\u2019Leary RS, Popescu NC, LaRochelle WJ. Localization of the human stat6 gene to chromosome 12q13.3-q14.1, a region implicated in multiple solid tumors. Genomics. 1998;52:192\u2013200.","journal-title":"Genomics"},{"key":"2692_CR259","doi-asserted-by":"publisher","first-page":"153477","DOI":"10.1016\/j.prp.2021.153477","volume":"223","author":"G Karpathiou","year":"2021","unstructured":"Karpathiou G, Papoudou-Bai A, Ferrand E, Dumollard JM, Peoc\u2019h M. STAT6: A review of a signaling pathway implicated in various diseases with a special emphasis in its usefulness in pathology. Pathol Res Pract. 2021;223:153477.","journal-title":"Pathol Res Pract"},{"key":"2692_CR260","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1158\/0008-5472.CAN-12-4318","volume":"73","author":"J Wei","year":"2013","unstructured":"Wei J, Wang F, Kong LY, Xu S, Doucette T, Ferguson SD, et al. miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. Cancer Res. 2013;73:3913\u201326.","journal-title":"Cancer Res"},{"key":"2692_CR261","doi-asserted-by":"publisher","first-page":"5759","DOI":"10.1158\/1078-0432.CCR-10-1095","volume":"16","author":"Y Guo","year":"2010","unstructured":"Guo Y, Nemeth J, O\u2019Brien C, Susa M, Liu X, Zhang Z, et al. Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer. Clin Cancer Res. 2010;16:5759\u201369.","journal-title":"Clin Cancer Res"},{"key":"2692_CR262","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1200\/JCO-25-01631","volume":"43","author":"IM Chen","year":"2025","unstructured":"Chen IM, Johansen JS, Theile S, Silverman LM, Pelz KR, Madsen K, et al. Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia. J Clin Oncol. 2025;43:2840.","journal-title":"J Clin Oncol"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02692-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02692-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02692-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T02:01:32Z","timestamp":1784080892000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02692-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":262,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2692"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02692-9","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"20 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"173"}}